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1. Introduction 
1.1 Liver anatomy and physiology 
The liver, the second largest organ of the human body, weights about 1500 g. 
It is located in the right upper quadrant abdominal cavity of the human body1. The 
liver is a vital organ and plays a major role in energy metabolism, which includes 
proteins related to synthesis, enzymes and cofactors, digestion, and the regulation of 
metabolic functions. Moreover, the liver is involved in the regulation of the body's 
protein, fat and carbohydrate metabolism, transformation, biliary excretion, and 
metabolism of toxic compounds and drugs2. As the first line of defence against 
ingested toxins and many infectious agents, the liver has evolutionarily conserved 
responses including the ability to regenerate and to protect itself against injury. 
The liver is composed of hepatic lobules constituted by parenchymal cells 
(hepatocytes and cholangiocytes) and non-parenchymal cells (NPCs) (Figure 1). 
Hepatocytes are the most numerous cells of the liver, represent 80% of total volume 
of the liver cells and the number accounted for about 60%3. NPCs numbers account 
for 40% of the total number of liver cells, but only 6.5% to the total liver volume, are 
localized in the sinusoidal compartment of the liver. Sinusoidal endothelial cells 
(SECs), Kupffer cells (KCs), hepatic stellate cells (HSCs), lymphocytes and oval cells 
are some of the NPCs that constitute the hepatic sinusoid3. SECs are fenestrated 
endothelium surrounding the sinusoids of the liver. They possess flattened shape 
and are united through adherent junctions. SECs have numerous vesicles in the 
cytoplasm and nuclei located in the center of the cell. The perforation between these 
cells is very large, which average diameter is about 100 µm, so that blood can easily 
come into contact with the hepatocytes microvilli through the space of Disse. KCs, 
which are the macrophages of the liver, are monocytes located in the lumen of the 
venous sinusoids. The numerous protrusions typical of cells of the macrophage, 
whose shape is variable and irregular, extend into the lumen of the sinusoid. Hepatic 
macrophages secrete potent inflammatory mediators and control the early phase of 
liver inflammation, playing an important part in innate immune defense. Moreover, 
during liver injury and inflammation, KCs secrete enzymes and cytokines that may 
damage hepatocytes and participate in the remodeling of ECM4. HSCs are placed 
 
 
 
   Introduction 
 5 
 
between the plates at the base of hepatocytes, and have a star-shaped or irregular.  
As the cells quiescent stage, their cytoplasm is rich in lipid vesicles containing vitamin 
A. During liver injury they become activated myofibroblasts with the lipid vesicles 
disappearing and produce ECM that lead to liver scarring and structural deformation, 
leading to the progression of liver fibrosis and injury5. Lymphocytes are also part of 
the innate immune system and help resist infection4. The oval cell is the liver-specific 
stem cell, a blast-like cell capable of self renewal and multipotent differentiation, 
which can only be identified in the setting of chronic liver injury when resident 
hepatocytes are unable to enter the cell cycle to restore liver mass. Evidence 
suggests that oval cells are bipotential, capable of differentiating into mature 
hepatocytes or cholangiocytes under different experimental conditions6. All these cell 
types are activated following hepatic injury7. 
 
Figure 1. The liver is composed of hepatocyte (parenchymal cell) and NPC, such as KC, SEC, 
HSC. Hepatocytes adhere to each other via a junctional complex formed by a tight junction, an 
adherence junction, and a gap junction. These cell environment and cell-cell interactions contribute to 
maintenance of liver functions and liver regeneration. Courtesy of Akaike Laboratory; source: 
http://www.akaike-lab.bio.titech.ac.jp/akaike/english/resarch/index.html 
 
1.2 Liver fibrosis 
 
1.2.1 Etiology and clinical signs of liver fibrosis 
 
The accumulation of ECM proteins during a long period results in the 
development of liver fibrosis8. The etiology of liver fibrosis in industrialized countries 
includes chronic HCV infection, alcohol abuse, and non-alcoholic steatohepatitis 
(NASH) or non-alcoholic fatty liver disease (NAFLD)9. Pathophysiology perspective, 
studies have shown that the accumulation of ECM distorts the hepatic architecture by 
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forming a fibrous scar. Hepatic fibrosis produces hepatocellular dysfunction and 
increased intrahepaticresistance to blood flow, which result in hepatic insufficiency 
and portal hypertension, respectively, and can trigger growth of hepatocellular 
carcinoma (HCC)10.  
 
1.2.2 Pathophysiology of liver fibrosis 
 
  Hepatic fibrosis is the result of the wound-healing response of the liver to 
prolonged injury8. After an acute liver injury (e.g., Drug-induced hepatitis), 
parenchymal cells regenerate and replace the necrotic or apoptotic cells. This 
process is associated with an inflammatory response and a limited deposition of ECM. 
If the hepatic injury persists, then eventually the liver regeneration fails, and 
hepatocytes are substituted with abundant ECM, including fibrillar collagen9. The 
distribution of this fibrous material depends on the origin of the liver injury. In 
cholestasis-induced liver fibrosis, the fibrotic tissue is initially located around portal 
tracts, while in alcohol-induced liver disease, it locates in pericentral and 
perisinusoidal areas11. As the disease progression of liver fibrosis, liver fibrosis is the 
major changes in the number and composition of the ECM, collagen band from 
bridging fibrosis to cirrhosis occurred12. In advanced stages, the liver contains about 
6 times higher than the normal state, including collagens (I, III, and IV), fibronectin, 
elastin, laminin, hyaluronan, and proteoglycans. Accumulation of ECM results from 
both increased synthesis and decreased degradation. Declined activity of MMPs 
(matrix metalloproteinases), which is responsible for the elimination of ECM, mainly 
due to an overexpression of their specific inhibitors (TIMPs)13. 
With the widespread use of the mouse models of hepatic fibrosis, extensive 
studies have revealed key gene-mediated hepatic fibrogenesis14. Genes regulating 
hepatocellular apoptosis and/or necrosis (e.g. TNF-R1, FasR and DR5) influence the 
extent of hepatic damage and the subsequent fibrogenic response15-16. Genes 
regulating the inflammatory response after injury (e.g., IL-1β, IL-6, IL-10, and IL-13, 
IFN-γ, SOCS-1, and OPN) determine the fibrogenic response to injury17-19. In addition, 
genes mediating ROS generation (e.g. catalase) regulate the progression of liver 
fibrosis20-21.  
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1.3 HSCs and liver fibrosis 
 
HSCs are normally quiescent cells and show a star-like appearance. When 
HSC is activated, they undergo excessive cellular proliferation and transdifferentiate 
into myofibroblasts which have a high degree of contractility22. Quiescent HSCs 
represent 5-8% of the total number of liver cells. They play a key role in storage and 
controlled release of retinoids22. The most characteristic structural feature of 
quiescent HSCs is the presence of numerous, large cytoplasmic lipid droplets, which 
are composed of retinoids, triglycerides, cholesterol and FFA5. Based on the 
presence of vitamin A, HSCs encompass an autofluorescence under the UV light 
radiation and can be distinguish their identification. In the normal liver, HSCs include 
diverse functions. As localization within the space of Disse, HSCs are proposed to be 
the key cell type that regulates hepatic blood flow and pressure23. In addition, studies 
have shown that the HSCs capable of expressing a variety of receptor proteins and 
secreted proteins that include receptors for ECM components, cytokines, growth 
factors, chemokines, vasoactive substances and several other ligands24. Moreover, 
HSCs are considered to serve as a hepatic progenitor cell and are essential in 
balancing the MMP/TIMP system25. 
When cultured on a plastic dish with the fetal calf serum, HSCs are easy 
attachment, proliferation, and spontaneous transdifferentiation. This phenomenon is 
as similar as observed with chronic liver diseases of HSC activation process. During 
this process, HSCs increase the expression of characteristic markers including α-
SMA and collagen type I that are considered to be indispensable event in the 
pathogenic sequence of fibrogenesis. The resulting phenotype produces a large 
variety of ECM indicative for fibrotic connective tissue and expresses a sundry of 
cytokines and chemokines triggering the fibrogenic response26. Activated HSCs 
express desmin and GFAP, PDGF, TGF-β and several other cytokines, as well as 
oxidative stress and lipid peroxidation products fuel the process of 
transdifferentiation27. The transdifferentiation process will further exacerbate by 
paracrine-acting mediators released from liver cells, for example hepatocytes, KCs 
and SECs, and from invading non-hepatic cells, such as platelets, lymphocytes and 
leukocyte subtypes28. 
Activation of HSCs in culture resembles its in vivo activation after chronic liver 
injury5. In comparison to their quiescent counterpart, they have a different gene-
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expression profile that particularly affects growth factors, nuclear receptors, 
cytoskeleton proteins and their receptors, cytokines and chemokines. Moreover, they 
change their morphology, their cellular ultrastructure, acquire contractile properties 
on a variety of cytokines and  chemokines29.  
Animal models of liver fibrosis, such as CCl4 treatment or surgical bile duct 
ligation (BDL) surgery, clearly show the role of HSC in liver fibrosis. In pathological 
conditions such as liver fibrosis, the phenotypic changes related with myofibroblastic 
transdifferentiation is a reduction of lipid droplets, loss of stored vitamin A, increased 
synthesis of collagen and α-SMA, reorganisation of the actin cytoskeleton, increased 
deposition of ECM and proliferation30-31. Recent studies using murine models of 
hepatic fibrosis have revealed a close interaction between inflammatory signals, 
monocytes/macrophages and HSCs for the initiation of fibrogenesis in vivo5. Actually, 
HSCs activation is driven by TNFα and other cytokines together with KCs. HSCs can 
be activated via TLR4 by various sources of bacterial lipopolysaccharide (LPS), such 
as that originating from intestinal flora. Activated HSCs produce chemokines that 
include MCP-1 or RANTES32. The release of these chemokines attracts monocytes 
from the peripheral blood into the injured liver. Infiltrating monocytes rapidly 
differentiate into inflammatory macrophages in the liver that produce a large number 
of TGF-β, which  is the main factor stimulating HSCs activation33  
 
 
1.4 Cell types involved in liver fibrosis 
 In the process of liver fibrosis, many experiments confirmed that collagen-
producing myofibroblasts are mainly derived from HSCs in vivo34. However, the 
following other cellular sources may contribute to ECM production in the liver as well 
(Figure 2). 
 
Figure 2. Sources of myofibroblasts in liver injury. 
Multiple sources of fibrogenic myofibroblasts are likely 
in liver injury depending on the site and nature of the 
injury. While resident HSCs appear to be the most 
likely source, periportal fibroblasts may be especially 
prominent in biliary injury, whereas BMCs and possible 
EMT may contribute as well. Courtesy of John P. 
Iredale35.  
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1.4.1 Portal fibroblasts  
These mesenchymal cells are considered to represent resident fibroblasts in 
the portal areas. Their activation may be especially important role to the liver fibrosis 
caused by cholestatic disease, which is characterized by a distribution in the portal 
tracts36. From the experimental evidence of cholestatic fibrosis model, portal 
fibroblasts can transdifferentiate into myofibroblasts following a pattern similar to the 
transdifferentiation of HSCs and further contribute to the fibrogenic process by 
triggering bile duct epithelia hyperproliferation37. 
 
1.4.2 Bone marrow-derived cells (BMCs)  
Presently, there are two distinct populations of BMCs known that could 
contribute to hepatic fibrogenesis. The first group are bone marrow-derived 
mesenchymal stem cells. The second option is fibrocytes. Unfortunately, yet more 
light needs to be shed on this issue as these experimental studies have proven to 
show rather limitation and potential flaw and more research needs to verify the role of 
BMCs in liver fibrosis38.  
 
1.4.3 Epithelial-to-mesenchymal transition (EMT) 
The EMT is an important process, which is characterized by a loss of cell 
adhesion function and repression of E-cadherin expression during embryonic 
development38. Recent studies indicated that EMT can be reactivated in pathological 
conditions and might thus represent a promising therapeutic target for the attenuation 
of liver fibrosis39-40. However, the concept of EMT has been severely argued among 
fibrosis researchers in recent years40-41. Thus, it is presently not clear if and to what 
extent EMT-related mechanisms contribute to liver fibrogenesis. 
 
1.5 Current treatment of liver fibrosis 
 
Several antifibrotic approaches exist. The removal of the causative agent is the 
most effective intervention in the treatment of liver fibrosis. This strategy has been 
proven to be effective in the etiologys of most chronic liver diseases42. For example, 
chronic HCV infection is the most extensively studied disease, and therapy (IFN-α 
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plus ribavirin) with viral clearance results in fibrosis remission. Importantly, nearly 
50% of the patients with cirrhosis have significantly eased42-43. 
Another method is the inhibition of HSCs activation by modulating either their 
activation and/or proliferation or promoting their apoptosis. Antioxidants such as 
vitamin E and S-adenosyl-L-methionine (SAM) inhibit HSCs activation and attenuate 
experimental liver fibrosis44. Another molecule that does inhibit the HSCs activation is 
IFN-γ45. Furthermore, the use of synthetic ligands was tested for peroxisome 
proliferators activated nuclear receptors (PPAR). All of these receptors are present 
on the surface of HSCs and especially PPAR-γ seems to inhibit the activation of 
HSCs46-47. 
Because inflammation precedes and promotes the progression of liver fibrosis, 
the use of anti-inflammatory drugs has been proposed to inhibit the fibrogenesis. 
Moreover, since TNFα is one of the major pro-inflammatory cytokines such as 
antibodies, soluble TNF-R has been used and tested in mouse models of hepatitis48. 
In addition to the above methods, a direct antagonist of collagen expression and 
usage of growth factors were used to treat liver fibrosis45. Moreover, recently usage 
of mesenchymal stem cells might also be a possible approach to regenerate an 
established liver fibrosis49-50. Overall, finally remains that liver fibrosis can potentially 
be targeted by several strategies. Time will tell us which strategy - drug treatment, 
antagonist usage, gene therapy or a combination method will be the treatment of 
choice for liver fibrosis. 
 
1.6 The JNK signaling pathway 
 
C-Jun N-terminal kinase (JNK) is a member of the MAPK family. These proteins 
are serine-threonine protein kinases, which are activated in response to a variety of 
extracellular stimuli and mediate signal transduction from the cell surface to the 
nucleus. Three major MAPKs include ERKs, JNKs, and p38 kinases51. Ten JNK 
isoforms have been identified and are encoded by three distinct genes, JNK1, JNK2, 
and JNK3, the transcripts of which are alternatively spliced to yield four JNK1 
isoforms, four JNK2 isoforms, and two JNK3 isoforms. JNK1 and JNK2 are the 
products of alternative splicing of a single gene and are expressed in almost all cells, 
including liver parenchymal cells, whereas JNK3 is mainly expressed in brain, heart, 
and testis52-53. 
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JNKs are activated in response to stimuli such as inflammatory cytokines, 
bacterial products, oxidative stress, pathologic and environmental stress (ischemia, 
hypoxia, as well as UV and ionizing radiation), toxins, drugs, endoplasmic reticulum 
(ER) stress, and metabolic changes, including obesity and hyperlipidemia52. The 
upstream pathway leading to JNK activation is a complex process governed by 
different signaling proteins. Actually, JNK phosphorylation is mediated by two MAPK 
kinases (MAPKKs) - MKK4 and MKK7 - that can cooperatively activate JNK. JNK 
targets are cellular processes, regulating proliferation, cell death, inflammation, and 
metabolism and acting either as transcription factors or by controlling protein 
degradation, localization, and signaling (Figure 2).  The substrates for JNK include c-
Jun, JunB, JunD, AF2, p53, c-Myc, Itch, IRS-1, JIP-1, Bcl-2, Bcl-xL, Bid, Bim, Bad, 
Bax, and Mcl-151-52, 54. 
 
MAPKKKASK-1 MEKK MLK TAK-1 TPL-2
MKK4 MKK7
JNK-1   JNK-2
MAPKK
MAPK
Cell survival 
p53, NF-κB, AKT, ERK
Transcription Factors
Nuclear Receptors
Bcl-2 family members
Ubiquitin ligases
Apoptosis 
(Caspase 3/8, Bid/Bax, PUMA, NOXA)
Cytokines T-cell ROS LPS UV light γ-irradiation
JNK TARGETS
RESPONSES
Proliferation
Cyclin D1, CDK
Inflammation
TNFα
Migration
ACTIVATORS
Wound healing  
Figure 3. The JNK signalling pathway . Stress-activated protein kinases (SAPK)/JNK are members 
of the MAPK family and are activated by a variety of environmental stresses, inflammatory cytokines, 
ROS and LPS. The membrane proximal kinase is a MAPKKK that phosphorylates and activates MKK4 
or MKK7, the SAPK/JNK kinases. SAPK/JNK translocates to the nucleus where it can regulate the 
activity of multiple transcription factors. 
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1.7 The role of JNK in liver injury 
 
A role for JNK in apoptosis is well established and the mechanism by which 
this occurs is controversial and appears to be stimulus- and tissue-specific55. One 
explanation for some of the differences could be the temporal aspect of JNK 
activation56. Recent studies demonstrate that both the transient and sustained 
phases of JNK activation contribute to the induction of gene expression. However, 
early transient JNK activation promotes cell survival, whereas prolonged JNK 
activation can mediate apoptosis52.  
  Several reports demonstrated that c-Jun – a crucial downstream target of JNK 
– is essential for liver regeneration as conventional c-Jun knockout animals die 
during embryonic development which has been linked to death of fetal liver cells57. In 
contrast, conditional hepatocyte-specific inactivation of c-Jun resulted in impaired 
hepatocyte proliferation during liver development and after partial hepatectomy58. 
Additionally, JNK inhibitors such as SP600125 have been used to study the 
relevance of JNK activation for liver regeneration59. These studies showed reduced 
hepatocyte proliferation during liver regeneration suggesting that JNK is necessary 
for liver regeneration. 
 Current research has demonstrated that JNK may also play important roles in 
other forms of cell death, including necrosis and autophagy. Ventura and colleagues 
have confirmed that JNK contributes to TNF-stimulated necrosis in cells when the 
NF-κB pathway is inhibited by promoting the production of cytotoxic ROS60. The anti-
apoptotic proteins are phosphorylated by JNK in vitro and transfection studies 
indicate that this phosphorylation may suppress the antiapoptotic functions of these 
proteins55. 
A number of studies suggest that the JNK genes are functionally redundant in 
animal development and cell growth regulation. Both JNK1 and JNK2 are required for 
regional specific apoptosis of the brain in early development, neural tube 
morphogenesis and T cell proliferation61. Aside, emerging evidence suggests that the 
JNK genes may play different roles in many instances. Thus, it has been reported 
that JNK1, rather than JNK2, is involved in cell proliferation. However, JNK2 inhibits 
cell growth62. Some authors have considered a prominent role of JNK1, but not JNK2, 
during TNF-induced apoptosis in vitro63 and in vivo64. Wang et al65 have thought 
while JNK2 is essential for TNFα mediated apoptosis JNK1 is not directly involved in 
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this pathway. A possible explanation for these findings could be the different 
molecular targets of JNK1 and JNK2. JNK1 acts pro-apoptotic via Itch activation and 
subsequent c-FLIP degradation leading to low c-FLIP levels, reduced inhibition of 
caspase 8 and increased apoptosis. In turn, JNK2 directly mediates caspase 8 
activation, via a yet unknown mediator66. 
 
1.8 The function of JNK in liver fibrosis 
 
NAFLD is a hepatic manifestation of the metabolic syndrome, which is 
characterized by obesity and insulin resistance. The spectrum of NAFLD ranges from 
simple steatosis to steatosis with hepatic inflammation and fibrosis, known as NASH. 
NASH is a high risk factor for cirrhosis. Studies have shown interesting information of 
role of JNKs in fatty liver diseases. For example, research using HFD and MCD diet 
revealed that the JNK genes appear to play a pivotal role in the pathogenesis of 
NAFLD, a spectrum of liver disorders whose main clinical sign is insulin resistance 
due to impaired IRS signalling67-68.  
The role of different JNK genes in the process of hepatic steatosis exists 
significant conflict69-70. A much remarkable distinction between the JNK1 and JNK2 
genes is the key role of JNK1 in the phosphorylation of the insulin receptor substrate-
1 (IRS-1), associated with insulin resistance and obesity71. Moreover, acute 
knockdown of JNK1 or JNK2 in a model of established steatosis showed that the 
hepatocyte damage and steatosis were attenuated only in JNK1 knockdown not in 
JNK2 knockdown owing to increase expression levels of Bim72. Several other studies 
also have highlighted the importance of JNK1 over JNK2 in lung fibrosis, gastric 
cancer, histone acetylation, Bcl2 phosphorylation, repression of the Wnt/β-catenin 
signaling, and myoblast differentiation73. Therefore, these results stress the 
importance to better understand the individual and synergistic roles of JNK1 and 
JNK2 as pivotal mediators of obesity and insulin resistance in order to define 
potential therapeutic targets. 
JNK is also involved in HSCs activation. Blocking JNK activity with small 
molecule drugs inhibited HSCs activation, shown by decreased expression of α-SMA, 
and reduced proliferation74. TGF-β, PDGF and angiotensin II up-regulate expression 
of α-SMA through activation of JNK. Both TGF-β and PDGF activate SMAD2 and 
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SMAD3 through JNK, resulting in HSC migration59. In addition, the role of different 
JNK genes is different for promoting HSC activation and proliferation. Jnk1-/- mice 
were protected from liver fibrosis, but Jnk2-/- mice showed significant fibrosis in 
cholestasis fibrosis model59.  
Together these data strongly suggest that JNK mediates many mechanisms that 
contribute to the pathogenesis of liver injury and more work is needed to better define 
the cell- and allele-specific role of JNK during liver fibrosis. 
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1.9 Aim of the study  
 
Hepatic fibrosis is a wound-healing response to chronic liver injury, which 
frequently results in cirrhosis and consequently in liver failure. Chronic liver injury 
triggers a persistent and continuous response which increases ECM deposition. 
JNKs are activated in response to stimuli such as inflammatory cytokines, bacterial 
products, ROS, toxins, drugs, and metabolic changes. The JNK genes have been 
suggested to have a role during HSCs activation and differentiation which suggests a 
potential role for JNK in liver fibrosis. However, the specific role of the JNK genes, 
and specifically of JNK1, during liver fibrogenesis is not yet defined. 
Therefore, in the present study we focused on the function and the cell-
specific role of JNK1 in an animal model of chronic liver injury in vivo. We addressed 
this task by combining general and hepatocyte-specific JNK1 knockout animals 
(Jnk1Δhepa). The different steps can be summarized as follows: 
 
1. To study the contribution of JNK1 in hepatocytes and NPCs to chronic liver injury: 
Here, WT, Jnk1−/− and Jnk1Δhepa mice were subjected to either bile duct ligation (BDL) 
or CCl4 for the induction of hepatic fibrosis. Thus, we analyzed whether JNK1 in 
hepatocytes or in NPCs has an impact on experimental liver fibrosis. 
 
2. To analyse the function of JNK1 in BMCs during liver injury: To investigate whether 
BMCs are essential in promoting liver fibrosis, we performed BMT. WT and Jnk1−/− 
mice were lethally irradiated and reconstituted with either Jnk1−/− or WT BMCs. Five 
weeks later, recipient mice were subjected to chronic CCl4 application or BDL surgery 
for 28 days. 
 
 3. To assess the role of JNK1 in HSCs in vivo and in vitro: Activated HSCs migrate 
and accumulate at the sites of tissue during chronic liver injury. Therefore, we tested 
the relevance of JNK1 during HSCs transdifferentiation into myofibroblasts. In these 
cells, proliferation, apoptosis and transdifferentiation were studied in vitro over a time 
period of 10 days.  
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2. Materials and Methods  
2.1 Materials  
2.1.1 Chemicals 
Reagent Manufacturer 
Ac-DEVD-AFC Fluorogenic Substrate  Biomol, Hamburg  
Acetic acid (glacial) 100% (CH3COOH)  Merck, Darmstadt  
Acetone (C3H6O)  VWR, Darmstadt  
Acrylamide 30%  Bio-Rad, Munich  
Agar-Agar  Becton Dickinson, Heidelberg 
Agarose Electrophoresis Grade  Serva, Heidelberg  
Albumin bovine  Sigma, Steinheim  
Ammonium peroxodisulfat (H8N2O8S2)  Roth, Karlsruhe  
Ampicilin  Sigma, Steinheim  
Aprotinin  Sigma, Steinheim  
Boric acid (H3BO3)  AppliChem, Darmstadt  
Bromphenol blue  Bio-Rad, Munich  
β-Mercaptoethanol  AppliChem, Darmstadt  
CHAPS (C32H58N2O7S)  Sigma, Steinheim  
Chloroform (CHCl3)  AppliChem, Darmstadt  
Collagen from rat tail  Sigma, Steinheim  
Complete Mini (protease inhibitors)  Roche, Mannheim  
Coomassie Brilliant Blue  Bio-Rad, Munich  
DAKO REAL Peroxidase Blocking Solution  Dako, Hamburg  
3,3 Diaminobenzidine tablets (Sigma fast)  Sigma, Steinheim  
DMF (N,N-Dimethylformamid) 
((CH3)2NC(O)H)  
Sigma, Steinheim  
DMSO (Dimethyl sulfoxide)  Sigma, Steinheim  
DNA standard  Invitrogen, Karsruhe  
DTT (Dithiothreitol) (C4H10O2S2)  Sigma, Steinheim  
EDTA (Ethylene Diamine Tetraacetate)   AppliChem, Darmstadt 
EGTA (Ethylene glycol tetraacetic acid)   AppliChem, Darmstadt 
Eosin  Sigma, Steinheim  
Ethanol (C2H5OH)  AppliChem, Darmstadt 
Ethidium bromide (C21H20BrN3)  Invitrogen, Karsruhe  
Fast Red Tablets  Roche, Mannheim  
Fetal bovine serum  Invitrogen, Karsruhe  
Formaldehyde 37% (CH2O)  Roth, Karlsruhe  
Gelatin from porcine skin Type A  Sigma, Steinheim  
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Glutaraldehyde (C5H8O2)  Roth, Karlsruhe  
Glycerin (C3H5(OH)3)  Roth, Karlsruhe  
Glycerol gelatin  Sigma, Steinheim  
Glycine (C8H9NO3)  AppliChem, Darmstadt 
Goat serum  Promocell, Heidelberg  
Haematoxylin  Sigma, Steinheim  
HEPES (C8H18N2O4S)  Roth, Karlsruhe  
Hydrogen peroxide 30% (H2O2)  AppliChem, Darmstadt  
Hydrochloric acid (HCl)  Merck, Darmstadt  
Isopropyl alcohol (C3H8O)  AppliChem, Darmstadt  
Magnesium chloride (MgCl2)  Merck, Darmstadt  
Methanol (CH4O)  VWR, Darmstadt  
Nonfat dried milk powder  AppliChem, Darmstadt  
Nonidet P-40  AppliChem, Darmstadt  
Novex Sharp protein standard  Invitrogen, Karsruhe  
Phenilenediamine dihydrochloride  Sigma, Steinheim  
Paraformaldehyd ((CH2O)n)  Roth, Karlsruhe  
Pefabloc SC Protease Inhibitor  Roth, Karlsruhe  
Penicillin-Streptomycin  Invitrogen, Karsruhe  
peqGOLD RNA PureTM  Peqlab, Erlangen  
PhosSTOP  Roche, Mannheim  
PIPES (C8H18N2O6S2)  Sigma, Steinheim  
PMSF (Phenylmethylsulphonyl fluoride)  Roth, Karlsruhe  
Poly dI:dC  GE Healthcare, Munich 
Ponceau S  Sigma, Steinheim  
Potassium chloride (KCl)  Merck, Darmstadt  
Potassium Ferricyanide (C6N6FeK3)  Sigma, Steinheim  
Potassium Ferrocyanide (C6N6FeK4)  Sigma, Steinheim  
Roti-Histokit  Roth, Karlsruhe  
SDS (Sodium Dodecylsulfate) (NaC12H25SO4) Roth, Karlsruhe  
Serum, human  Sigma, Steinheim  
Serum, mouse  Sigma, Steinheim  
Serum, rabbit  Sigma, Steinheim  
Sodium acetate anhydrous (C2H3NaO2)  AppliChem, Darmstadt 
Sodium azide (NaN3)  AppliChem, Darmstadt 
Sodium tetraborate anhydrous (Na2B4O7)  Sigma, Steinheim  
Sodium carbonate (Na2CO3)  Merck, Darmstadt  
Sodium chloride (NaCl)  AppliChem, Darmstadt 
Sodium fluoride (NaF)  Sigma, Steinheim  
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Sodium hydroxide (NaOH) 1 mol/l  AppliChem, Darmstadt 
Sodium hydroxide pellets  Merck, Darmstadt  
Sodium orthovanadate (Na3VO4)  AppliChem, Darmstadt  
Sodium thiosulfate (Na2S2O3)  Sigma, Steinheim  
SuperSignal West Pico Substrate  Thermo Scientific, Bonn  
TEMED (Tetramethylethylenediamine)  Bio-Rad, Munich  
Tissue Tek  Dako, Hamburg  
Trichloroacetic acid (C2HCl3O2)  Merck, Darmstadt  
Trypsin Inhibitor  Sigma, Steinheim  
Tris (C4H11NO3)  AppliChem, Darmstadt  
Tri-sodium citrate dihydrate 
(Na3C6H5O7·2HCl)  
Roth, Karlsruhe  
Triton X100  Roth, Karlsruhe  
Trypton  Becton Dickinson, Heidelberg  
Tween® 20  Sigma, Steinheim  
Vectashield mounting medium with DAPI  Dako, Hamburg  
Vectastain ABC Kit  Dako, Hamburg  
Xylene  VWR, Darmstadt  
 
2.1.2 Standard buffer and media 
Buffers Manufacturer 
Phosphate buffered saline (PBS)  PAA, Cölbe  
Restore Western Blot Stripping Buffer  Thermo Scientific, Bonn  
Roti Block 10x  Roth, Karlsruhe  
Rothiphorese10x SDS PAGE  Roth, Karlsruhe  
TAE 50x  AppliChem, Darmstadt  
 
Cell culture medium Manufacturer 
DMEM (Dulbeco’s Modified Eagle Medium)  PAA, Cölbe  
EBSS (Earle's Balanced Salt Solution) w/o Ca2+ & Mg2+  Invitrogen, Karsruhe 
EBSS (Earle's Balanced Salt Solution) with Ca2+ & Mg2+  Invitrogen, Karsruhe 
HBSS (Hank’s Balanced Salt Solution)  PAA, Cölbe  
RPMI (Roswell Park Memorial Institute)  PAA, Cölbe  
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2.1.3 Standard kits and enzymes 
 
Kit / Assay Manufacturer 
BIO-RAD Protein Assay  Bio-Rad, Munich  
In Situ Cell Death Detection Kit, Fluorescein  Roche, Mannheim  
Omniscript RT Kit  Qiagen, Hilden  
OxiSelect Oxidative DNA Damage Quatitation Kit (AP 
sites)  
Cell Biolabs / Biocat, 
Heidelberg 
 
Enzyme Manufacturer 
Collagenase Type II  CellSystems, Troisdorf  
HotStarTaqTM Master Mix  Qiagen, Hilden  
Proteinase K – Solution  AppliChem, Darmstadt  
ReadyMixTM redtaqTM PCR reaction mix with MgCl2  Sigma, Steinheim  
RNAse  Sigma, Steinheim  
SYBR® GreenERTM qPCR Super Mix  Invitrogen, Karlsruhe  
 
2.1.4 Antibodies used for immunostaining and/or western blot 
 
Primary Antibody Catalog Number  Company  
α-SMA A2574 Sigma 
CD11b  550282  BD  
Cleaved caspase-3  #9661  Cell Signaling  
CK19 12-3900 Santa Cruz 
CollagenI α1 BT-5014-10 BioTrend 
Cyclin A sc-596 Santa Cruz 
Cyclin D sc-450 Santa Cruz 
F4/80  MCA497GA  AbD serotec  
Ki-67  6013874 Leica 
PCNA  13-3900  Invitrogen  
JNK1 3708s Cell Signaling  
JNK2 4672s Cell Signaling 
JNK 9252s Cell Signaling 
pJNK1/2  9251  Cell Signaling  
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Secondary Antibody  Catalog Number  Company  
Anti-rabbit HRP  #7074  Cell Signaling  
Anti-mouse HRP  sc-2954  Santa Cruz  
Anti-goat HRP  sc-2768  Santa Cruz  
Anti-rat HRP  sc-2956  Santa Cruz  
Alexa Fluor488 anti-mouse  A-11059  Invitrogen  
Alexa Fluor 488 anti-rabbit  A-11008  Invitrogen  
Alexa Fluor 546 anti-rabbit  A-11071  Invitrogen  
Alexa Fluor 594 anti-rabbit  A-11072  Invitrogen  
 
2.1.5 Primer sequences used for qRT-PCR 
 
Gene  Forward  Reverse  
α-SMA ATG AAG CCC AGA GCA AGA GA  ATG TCG TCC AGT TGG TGA T 
Collagen1α GGA AAC CTC TCT CGC CTC TT GAA CAG GGT GTT CCT GAG A 
CK19 CGT ACC CCC AAA GGA AGA CA TCA GAC CTG CGT CCC TTT TT 
CcnA2 GTG GTG ATT CAA AAC TGC CA  AGAGTGTGAAGATGCCCTGG  
CcnD1 AAG CAT GCA CAG ACC TTT GTG G  TTCAGGCCTTGCATCGCAGC  
CcnE1 TCC ACG CAT GCT GAA TTA TC  TTGCAAGACCCAGATGAAGA  
GAPDH TGT TGA AGT CAC AGG AGA CAA CCT AAC CTG CCA AGT ATG ATG ACA TCA 
IL-1α TGG GAG CCC TTT CAT CAT GAT AAG GAC GGG AGG GAG AAA GAC T 
IL-6 CTT CCA TCC AGT TGC CTT CTT  AAT TAA GCC TCC GAC TTG TGA AG  
MMP2 GGC AAT GCA GAT GGA CAG CC CAT AGT CCT CGG TGG TGC C 
TGF-β1 AAA AAC CAA AGC CCA AAA AGC TA ATG ACT CAC ACT GAC GCA GAA AA 
TIMP1 GGT CCG AGT TGC AGA AGG C GGC ATC TGG CAT CCT CTT G 
TNF-α CAT TCG AGG CTC CAG TGA ATT C  GAA ACA CAA GAT GCT GGG ACA GT 
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2.1.6 Primer sequences used for genotyping PCR 
 
Mouse strain  Primer name  sequence  
JNK1 fw CAC ATA CAC TCA GTG GAT CT 
re CAC TAT TGC CTT AAG ACT CC 
fm  CTG ATC TTC CAG ATA ACT GC 
JNK2 fw TCC AGT ACA GCG CGG CTG AA 
re GCA GCA GCC CTC AGG ATC CT 
fm  TCT GAC GTC CTG GGC TGG AC 
pAlb-cre fw CGG GTG AAC GTG CAA AAC AGG CTC  
re CTT GCA TGA CCG GTA TTG AAA CTC CAG 
JNK1Δhepa fw GAA CCA CTG TTC CAA TTT CCA TCC 
re GGA TTT ATG CCC TCT GCT TGT C 
 
2.1.7 Instruments and other equipment 
 
Instrument Manufacturer 
AxioImager Z1  Carl Zeiss, Jena  
Blotting chamber Trans-Blot cell  Biorad, Munich  
Bright Field Microscope DM1000  Leica, Wetzlar  
Cell culture bench BSB6A  Gelaire Flow Laboratories, Meckenheim  
Cell incubator Haereus BB 6220  Thermo Scientific, Dreieich  
Centrifuge Eppendorf Tabletop 5417  Eppendorf, Hamburg  
Centrifuge Heraeus-Kendro Megafuge 1.0R  Thermo Scientific, Dreieich  
Centrifuge Heraeus Pico 17  Thermo Scientific, Dreieich  
Cryostat HM 550  Microm Thermo Scientific, Dreieich 
DISKUS Z16 APO  Leica, Wetzlar  
FACS Canto II Flow Cytometer BD, Erlangen 
FUJI FILM LAS-4000  FUJI FILM Europe, Düsseldorf  
Gel chamber Subcell GT  Biorad, München  
Gel chamber   Peqlab, Erlangen  
Homogenizer  Janke & Kunkel, Staufen  
Microcentrifuge IR 220 VAC  Roth, Karlsruhe  
Real-Time PCR System 7300  Applied Biosystems, Darmstadt 
Thermocycler T3000  Biometra, Göttingen  
Thermomixer  Eppendorf, Hamburg  
Vortex Reax top  Heidolph, Nürnberg  
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Animal experiment consumables  Manufacturer  
General chow for rodents  Altromin, Lage  
Hematocrit capillary  Hirschmann Laborgeräte, Eberstadt  
Heparine (Liquemin(R))  Roche, Mannheim  
Injection needles Sterican(R)  Braun, Melsungen  
Isoflurane  Abbott, Ludwigshafen  
Ketamin 10%  CEVA TIERGESUNDHEIT GmbH, Düsseldorf  
Micro tube (1,1 ml Z-Gel)  Sarstedt, Nümbrecht  
Sodium chloride 0,9% (NaCl)  DeltaSelect, Dreieich  
Sunflower seed oil  Sigma, Steinheim  
Surgical instruments  FST, Heidelberg  
Syringe Omnican(R)  Braun, Melsungen  
Xylazin 2%  Bernburg Medistar, Holzwickede  
 
 
Plastic and Glassware Manufacturer 
Beakers (10 – 1000 mL)  Schott-Duran, Mainz  
Bottles (25- 2000 mL)  Schott-Duran, Mainz  
SuperFrost slides  Roth, Karlsruhe  
Pasteur pipettes  Brand, Giessen  
96-well plates for RNA/DNA measurement  Greiner Bio-one, Frickenhausen 
96-well plates for protein measurement  Greiner Bio-one, Frickenhausen 
96-well plates for Real-Time PCR  StarLab, Ahrensburg  
Pipettes tips with filter for liquid handling  VWR, Darmstadt; BioHit, Rosbach v.d. Höhe; 
Biozym, Hess. Oldendorf  
Reaction tubes (0,5 – 2mL)  Eppendorf, Hamburg  
8 vial strips for PCR (0,2mL)  Sarstedt, Nümbrecht  
Reaction tubes 15mL  Sarstedt, Nümbrecht  
Reaction tubes 50 mL  GreinerBio-one, Frickenhausen 
Sterile pipettes (2-50mL)  Sarstedt, Nümbrecht  
Cell Strainer (70 μm)  BD, Erlangen  
Cryotubes 1,5 mL  Nunc, Langenselbold  
6; 12; 24-well plates  BD-Falcon, Heidelberg  
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2.2 Methods 
 
2.2.1 Bile duct ligation 
 
8-10 weeks-old mice were narcotized using 0.01% Xylazin hydrochloride/ 
1% Ketamin hydrochloride mixture, diluted in 0.9% NaCl. Per each 10 g body 
weight of the mouse, 100 μl of the narcotization-solution was administrated. 
After reflex control and affirmation of narcotization, the abdominal wall was 
sterilized by using Antifect®. Afterwards, an abdominal midline skin incision is 
made through the abdominal musculature by 1.5 cm long cut. The lobes of the 
liver are gently retracted to expose the bile duct. The bile duct then is carefully 
ligated with two pieces of sutures that one is in dorsal and the other is ventral to 
the bile duct. A small incision is used between both ligatures to ensure blocking 
of the bile duct. The abdominal musculature and skin are closed with 
absorbable suture by a continuous fissure. Subsequently, mice were received 
150 μg Temgesic® i.p. to avoid pain-induced stress. 
 
2.2.2 Bone marrow transplantation 
 
 a)  Treatment of donor mice: BMCs are isolated from euthanized donor mice. 
The concentration of cells is 107 cells /ml and each lethally irradiated mouse will 
receive a single intravenous (tail vein) or retro-orbital injection of donor BMC (1 x 106) 
cells. 
      
b)  Treatment of recipient mice: Irradiation of recipient mice is performed by using 
a cobalt irradiator in one of the barrier facilities. Mice are placed into a rotating pie-
shaped holder (to limit mobility and insure equal irradiation), which is then secured in 
the irradiator to deliver a dose of 6.8 G. The mice will be in the irradiator 8 minutes. 
Irradiation is repeated 4 h later for a total dose of 13.6 G (split dose irradiation is 
used to limit the non-hematopoietic toxicity - usually intestinal damage). Irradiated 
mice are injected within 18 h after the second irradiation via the tail vein with donor 
BMCs (1 x 106) diluted in 100 μl of sterile PBS. Alternatively, the cells may be 
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injected retro-orbitally into anesthetized mice. Recipient mice are maintained on 
antibiotic-containing water for approximately 2 weeks.  
 
2.2.3 Isolation of HSCs with FACS Sorting 
 
All cells were prepared from adult male C57BL/6 mice weighting approximately 
35 g, with free access to a standard chow diet and water. HSCs were isolated 
following the collagenase method, adapted to the murine system. Two animals each 
were taken for individual cell preparations. They were anesthetized with an 
intramuscular injection of Ketamin and Xylazin, and livers perfused via the portal vein 
with pronase and collagenase. The liver capsules were removed, tissues 
homogenized and further digested in a solution containing DNase I. The resulting cell 
suspensions were filtered through a nylon mesh, centrifuged and washed in ice cold 
Hanks buffered standard saline (HBSS; PAA Laboratories GmbH, Linz, Austria) 
containing 0.25% (w/v) BSA. HSCs were further purified by a single-step density 
gradient centrifugation with 8.2% (w/v) Nycodenz (Axis-Shield Point-of-Care Division, 
Oslo, Norway). HSCs were collected by aspiration of the white top layer of the 
gradient. 
After this step our team have established protocols to isolate HSCs by FACS5. 
HSCs from rats were purified by cell sorting using simply their high side scatter of 
incident light. Starting from crude cell fractions that were 50–70% enriched by 
conventional density centrifugation, the obtained cell purity after sorting (in which 1.4 
± 0.4 million cells were sorted per hour) was found to be over 96% and the viability of 
resulting cells was approximately 90%, as measured by Trypan blue exclusion testing. 
Freshly isolated HSCs were washed and plated in 6-well plates (Falcon) at a density 
of 150.000 cells per well and cultivated in DMEM supplemented with 10% FCS 4 
mmol/l L-Glutamine and 4 mmol/l Penecillin/Streptomycin (PAA, Pasching, Austria). 
After 6-8 h cells were attached and medium was changed. At indicated time points 
(day 1, 4, 7, 10 after isolation, respectively), cells were harvested with Accutase© 
(eBioscience, Frankfurt, Germany), washed with phosphate buffered saline and fixed 
with 4% PFA for 25 min. After fixation cells were stained as required. 
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2.2.4 Microarray analysis 
 
RNA was isolated from mouse livers using TRIzol reagent and purified with the 
RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's 
instructions. Concentrations and purity of RNA samples were determined on a 
NanoDrop ND-1000 spectrophotometer (Isogen, Maarssen, Netherlands). RNA 
integrity was checked on an Agilent 2100 bioanalyzer (Agilent Technologies, 
Amsterdam, The Netherlands) with 6000 Nano Chips. RNA samples from 3 mice per 
experimental group were used for microarray analysis. Samples were hybridized on 
Affymetrix GeneChip Mouse Genome 430 2.0 arrays in the microarray core 
laboratory of the Nutrigenomics Consortium at Wageningen University, The 
Netherlands. Hybridization, washing, and scanning of the arrays were performed 
according to standard Affymetrix protocols. Array images were processed using 
packages from the Bioconductor project75. Probe sets were redefined according to 
Dai76. Probes were assigned to unique gene identifiers, in this case Entrez IDs. 
Arrays were normalized with the Robust Multi-array Average (RMA) method. 
Differentially expressed probe sets were identified using intensity-based moderated 
paired t-statistics. P values were corrected for multiple testing using a false discovery 
rate (FDR) method.  
 
2.2.5 Housing and breeding of mice 
 
Animal husbandry and procedures were approved by the authority for 
environment conservation and consumer protection of the state North Rhine–
Westfalia (LANUV, Germany) and the University Hospital RWTH Aachen Animal 
Care Facility’s guidelines. For our study we used mice of male gender with 
constitutive deletion of Jnk1−/− and Jnk1Δhepa mice and WT littermates from 
heterozygous breeding couples. 
 
2.2.6 Induction of liver fibrosis in mice 
 
Experiments were performed with age-matched male mice at the age of 7 to 8 
weeks. Mice were treated with CCl4, (Merck; 0.6 mL/kg of body weight) diluted in 
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corn oil and BDL. Control animals were treated with corn oil only and sham. To 
induce CCl4 mediated chronic liver injury, mice (n=9-10 per group) received a single 
i.p. injection of CCl4 and were sacrificed 72 h after the last injection. The same 
number of mice were performed by BDL and sacrificed after 4 weeks. 
 
2.2.7 Genotyping  
 
The correct genotypes were verified by PCR analysis. DNA was prepared from 
fresh mouse tail biopsies using NID buffer. Mouse tails were digested with 200 μl of 
NID buffer and 1 μl of proteinase K at 56°C overnight. Enzyme activity was stopped 
by heating at 95°C for 5 minutes. The tairs were shortly spun down and 2 μl of the 
supernatant was used for PCR reaction. 
NID buffer content End concentration 
KCl 0.05 M 
Tris 0.01 M 
MgCl2 2 mM 
Gelatine type 3 0.1 mg/ml 
NP-40 0.45 % 
Tween 20 0.45 % 
 
PCR reaction and programs were as follows: 
Reaction volume 25 μl 
Primer sense (0,1nmol) 1 μl 
Primer antisense (0,1nmol) 1 μl 
Polymerase mix * 12.5 μl 
dH2O 8.5 μl 
DNA template 2 μl 
* ReadyMixTM redtaqTM or HotStarTaqTM Master Mix 
 
PCR products were separated by size on 2% (w/v) agarose gels. The agarose 
was boiled in TAE buffer, cooled at RT for 5-10 min, and 0.4 μg/ml ethidium bromide 
(EtBr) was added. 5x loading dye were added to the samples before application to 
the gel slots. Gels were run in TAE at 100-150 V. DNA markers were used to 
determine the specific size of fragments. EtBr, which intercalates into the DNA, 
enables the visualisation of the DNA on a UV-transilluminator. 
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2.2.8 Blood sampling and serology  
 
Blood sampling was performed in mice under transient anesthesia with 
isoflurane by penetrating the retro-orbital sinus with a glass capillary. Blood samples 
were collected in a serum tube and centrifuged at 5000 g for 10 minutes. Serum 
was transferred into a fresh tube and stored at -20°C. Serum transaminases are 
specific markers for liver damage. For this study, ALT and AST were measured in 
the clinical laboratories of the Institute of Clinical Chemistry and Pathobiochemistry, 
UK Aachen. 
 
2.2.9 Liver perfusion and isolation of primary hepatocytes  
 
The mice were anaesthetized by intraperitoneal injection of ~300 μl of Ketamin-
Xylazin solution. Anesthetized mice were immobilized with tape on all four limbs, the 
abdomen was opened and intestine was moved aside to expose the portal vein. The 
cannula was inserted in the portal vein and was fixed with a nylon monofilament wire 
to avoid that the blood pressure removes the needle at the beginning of the perfusion. 
Perfusion was started with 30 ml solution A, pH 7.4. As soon as the perfusion is 
started, the hepatic vein was immediately cut to allow perfusate to run out. Liver was 
perfused with a flow rate of 5 ml/min. Next, the liver was perfused with 30 ml of B 
solution pH 7.4. Finally, perfusing was switched to solution C with collagenase. At 
this stage the hepatic tissue was rapidly disaggregated. The tissue was collected and 
transferred into a plate, gallbladder was removed, and the liver tissue is swirled 
around to wash hepatocytes out.  
 
Perfusion solutions Content Amount 
Solution A EBSS without Ca2+ & Mg2+ 
EGTA 
50 ml 
100 mM 
Solution B EBSS with Ca2+ & Mg2+ 
HEPES, pH 7.4 
30 ml 
10 mM 
Solution C EBSS with Ca2+ & Mg2+ 
HEPES, pH 7.4 
Collagenase 
Soybean trypsin inhibitor 
50 ml 
10 mM 
0.3 mg/ml 
0.04 mg/ml 
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Hepatocytes and remaining tissue were collected in 5 ml DMEM and filtered 
through a 70 μm cell strainer. Cells were centrifuged at 500rpm for 1min at room 
temperature. Pellet was washed with PBS twice. Supernatant was removed and the 
pellet was resuspended in 20 ml high glucose DMEM supplemented with serum (10% 
FCS) and antibiotics (Penicillin, Streptomycin). The hepatocytes were counted and 
plated on precoated plates (Collagen from mouse tail). Mouse primary hepatocytes 
were cultured in DMEM/high glucose media supplemented with 10% FCS in a 
humidified atmosphere containing 5% CO2 at 37°C. The cells were grown in 100 mm 
dishes, 6-well or 96-well plates. The cells were allowed to settle down and adhere to 
culture dishes for 4-5 h and then the medium was replaced with fresh one or 
immediately stimulated. 
 
2.2.10 RNA extraction, cDNA preparation, Real-Time PCR  
 
RNA was extracted from mouse livers or primary hepatocytes using peqGOLD 
RNA PureTM (Peqlab) following manufacturer’s instructions. A piece of liver tissue 
was minced in peqGOLD RNA with an electric homogenizer. Lysates were incubated 
at RT for five minutes. After addition of 0.2 volumes of chloroform to the supernatants 
followed by centrifugation at 12000 g, the upper phases were incubated 10 minutes 
with isopropanol and RNA was pelleted by centrifugation at 12000 g at 4°C. The 
pellets were washed tiwce with 1 ml of 70% ethanol, air dried for 5 minutes and 
eluted in RNAse-free water. RNAs were quantified by spectrophotometry at an optical 
density (OD) of 260 nm. A 260/280 ratio ≤2.0 and ≥1.8 was considered high purity. 
 
Reverse transcription reaction mix Volume per reaction 
10x Buffer RT 2 μl 
dNTP mix 2 μl 
Oligo DT 2 μl 
Omniscript Reverse transcriptase 1 μl 
Template RNA (1μg/μl) 2 μl 
Total reaction volume 20 μl 
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Reverse transcription was performed using an Omniscript kit (Qiagen) according 
to the manufacturer’s protocol. Reactions were carried out in 20 μl volumes. 
Reactions were incubated in a PCR thermocycler at 37°C for 60 min, and 95°C for 5 
min and then cooled to 4°C. After reverse transcriptase, samples were diluted by 
adding purified water.  
For real-time quantitative RT-PCR, the Real-Time PCR System (AB 7300) was 
used. RT-PCR was performed in duplicate in 25 μl reaction volumes. Three-step 
PCR cycling was carried out as follows: 50 °C for 2 min (1 cycle), 95°C for 10 min (1 
cycle), 95°C for 15 s, and 60°C for 1 min (40 cycles). At the end of the PCR, 
baselines and threshold values were established using AB 7300 System SDS 
software, and the Ct values were exported to Microsoft Excel for analysis. Expression 
of mRNA was calculated using a relative quantification method 77, which determines 
the relative quantification of a target gene in comparison to a control gene. Analysis 
was carried out using the sequence detection software. This software calculates the 
Ct for each reaction and uses it to quantify the amount of starting template in the 
reaction. The relative expression ratio of a target gene is calculated based Ct 
deviation of an unknown sample versus a control and is expressed in comparison to 
the reference gene GAPDH.         
 
Real-time PCR reaction mix Volume per reaction 
Primer sense 2 μl 
Primer antisense 2 μl 
SYBR green 12.5 μl 
cDNA 5 μl 
dH2O 3.5 μl 
Total reaction volume 25 μl 
 
2.2.11 Protein concentration measurement  
 
The concentration of whole protein extracts was performed using BIO-RAD 
Protein Assay reagent. This technique was first described by Bradford et al78 and 
based on the absorbance maximum for an acidic solution of Coomassie Brilliant Blue 
G-250 shifts from 465 nm to 595 nm when binding to protein occurs. According to 
manufacturer’s protocol protein and standard were measured in a spectrophotometer 
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at OD595. The OD595 of each sample was compared to a standard curve prepared 
with BSA.  
 
 
2.2.12 Western Blot  
 
Protein samples were separated electrophoretically on 10%, 12% or 15% 
denaturing SDS-polyacrylamide gel or on pre-cast 4-12% polyacrylamide gel 
(Invitrogen). Gel and buffer were prepared according to table (see below). 
In short, 6 times protein loading buffer was added to each sample in 
appropriate volumes and samples were boiled at 96 °C for 5 min before loading to 
the gel slot. Separation was performed in 1x SDS running buffer at 80 V overnight or 
in MOPS running buffer at 120 V for approximately 2 h (pre-cast gel system). For 
immunological detection, the separated proteins in gel were transferred to a 
nitrocellulose membrane. 
 
Reagent Resolving Gel 
Percent 15% 10% 12.5% 
dH2O 12.3 ml 20 ml 16.4 ml 
1.5M Tris-HCl, pH 8.8 12.5 ml 12.5 ml 12.5 ml 
0.5M Tris-HCl, pH 6.8 - - - 
30% Acrylamide 24.35 ml 16.5 ml 20.3 ml 
10 % SDS 500 μl 500 μl 500 μl 
10 % APS 500 μl 500 μl 500 μl 
 
A wet blotting chamber was used to transfer the separated proteins from the 
polyacrylamide gel to a nitrocellulose membrane. Whatman paper, nitrocellulose 
membrane and polyacrylamide gel were soaked in transfer buffer. Transfer was 
performed according to standard proceedings. 
Successful transfer was confirmed by Ponceau Red staining. For 
immunological detections, the non-specific binding sites were blocked for 1 hours in 
2.5% non-fat dry milk diluted in PBS-Tween (PBST) or in 1x Roti-block. The 
membrane was shortly washed and then incubated overnight at 4°C in PBST with 
primary antibody at optimized dilutions. The membrane was washed 3x10 min in 
PBST and then incubated with the secondary antibody diluted 1:2000 in PBST for 1h 
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at RT. After incubation, the membrane was washed 3x5 min in PBST and then 
incubated in ECL Substrate (Pierce) for 5 min. The membrane was exposed to 
hyperfilm (Amersham) or a digital detection system.  
 
2.2.13 Immunofluorescence staining  
 
Cryopreserved sections were dryed in air 7 minutes. Sections (5 μm), from 
mouse livers, were fixed with 4% PFA for 15 min and washed with PBS for 3 x 5 min. 
All subsequent steps were carried out at RT in the humidified chamber. PBS 
containing 5% goat serum and 0.3% Triton was used for blocking for one hour 
followed by an overnight incubation with primary antibody in blocking solution at 
optimized dilutions at 4°C. Slides were washed with PBS for 3 x 5 min and incubated 
with secondary antibody labelled with Alexa fluorescent dye in blocking buffer for one 
hour at RT. Slides were washed with PBS for 3 x 5 min. Nuclei were counterstained 
with DAPI in mounting medium.  
 
TUNEL (TdT-mediated dUTP nick end labelling) staining is an established 
method for in situ labelling of DNA strand brakes that occur early during apoptosis. 
Terminal deoxynucleotidyl transferase (TdT) is used to introduce labelled nucleotides 
into partially degraded DNA. Liver cryosections were fixed with 4% PFA for 45 min 
and rehydrated with PBS for 3 x 10 min. Sections were treated with 3% H2O2 in 
methanol for 10 min, and then permeabilized with 0.1% Triton 100x, 0.1% Na-citrate 
for 2 min at 4°C. Slides were washed with PBS and stained with TUNEL mix (1μl 
enzyme, 9 μl TUNEL dilution buffer, 90 μl buffer) in humidified chamber overnight at 
4°C. After 3 x 10 min washing with PBS stained sections were mounted with DAPI 
mounting medium. The percentage of TUNEL positive cells was counted and set in 
percentage relationship to TUNEL negative. 
 
2.2.14 Immunohistochemistry  
 
Paraffin embedded sections were dewaxed and rehydrated with xylene and 
decreasing percentages of ethanol. Antigen retrieval was performed by cooking 
sections in sodium citrate buffer for 6 minutes in a microwave (Do not let the slides 
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go dry). This step enhances the availability of the antigen. After cooling for 10 
minutes, sections were rinsed in running tap water and endogenous peroxidases 
were quenched for 10 minutes. Sections were washed under running water, washed 
2 x 5 minutes in PBS. Following blocking with Avidein D blocking reagent for 15 
minutes at RT and with Biotin blocking reagent for 15 minutes at RT, sections were 
blocked in PBT (PBS, 0.1% BSA, 0.2% TritonX-100) and then incubated overnight 
with primary antibody (1:1000) at 4°C in a humid atmosphere. Slides were washed 
twice with PBS and the secondary antibody (1:200) was applied for 1 hour at RT in 
humidifying box, the parallel the HRP-ABC solution was made and incubated at least 
30 minutes at RT prior to use. Sections were incubated with HRP-ABC solution for 1 
hour at RT in a humidified box. After washing twice in PBS, signal was developed 
with DAB and counterstained with hematoxylin. Dehydrating was performed 
increasing percentages of ethanol and xylene, mounted with Roti-histokit. 
 
 
2.2.15 Statistical analysis 
 
All data are expressed as mean ± standard deviation of the mean. Statistical 
significance was determined by two-way analysis of variance followed by a Student’s 
t test or by one-way ANOVA of GraphPad software. P values less than 0.05 were 
considered   significant.
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3．RESULTS 
 
3.1 JNK1 in hepatocytes has no impact on hepatic injury during experimental 
liver fibrosis.  
 
To investigate the relevance of hepatocyte-specific JNK1 expression for liver 
injury, we generated hepatocyte-specific JNK1 knockout mice (Jnk1Δhepa). Besides 
Jnk1Δhepa animals constitutive Jnk1-/- and respective WT controls (floxed mice) were 
included in this analysis. Primary hepatocytes from the different animal strains were 
isolated and JNK1 protein expression was studied. These results confirmed lack of 
JNK1 expression in primary hepatocytes derived from Jnk1-/- and Jnk1Δhepa in 
contrast to WT mice (Figure 4A). Additionally, PCR of tail DNA confirmed the correct 
genomic changes in the JNK1 gene for the respective knockout strain (Figure 4B). 
A                                                                                B 
Figure 4. Lack of JNK1 expression in primary hepatocytes derived from Jnk1-/- and Jnk1Δhepa 
mice. (A) Primary hepatocytes of WT, Jnk1-/- and Jnk1Δhepa mice were examined by Western blot 
analysis by probing with antibodies to JNK1, JNK2 and GAPDH as indicated. (B) Ethidium Bromide 
gel showing the respective PCR results from tail DNA prepared from WT, Jnk1-/- and Jnk1Δhepa mice. 
The upper gel shows the detection of the WT and the constitutive JNK1 knockout locus, while the 
lower gel shows the WT and the floxed JNK1 gene locus.  
 
WT, Jnk1-/- and Jnk1Δhepa were treated with CCl4 or with BDL for 4 weeks. 
Macroscopic analysis of livers from CCl4-treated mice showed no apparent difference 
compared with corn oil-injected controls (Figure 5A). However, H&E staining of 
Jnk1Δhepa and WT livers treated for 4 weeks with CCl4 revealed more cellular damage 
and centrilobular congestion of inflammatory cells compared to Jnk1-/- mice (Figure 
5B).  
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A                                                                         B 
Figure 5. Macroscopic appearance and H&E staining of livers from CCl4-treated mice. (A) 
Macroscopic appearance of livers of WT, Jnk1-/- and Jnk1Δhepa mice 28 days after repeated CCl4 
njections. Corn-oil injections were used as controls. (B) Representative H&E staining of liver sections 
from livers of WT, Jnk1-/- and Jnk1Δhepa mice 28 days after repeated CCl4 injections. Corn-oil injections 
were used as controls.  
 
Macroscopic examination of 28 days-BDL-subjected liver specimens of WT and 
Jnk1Δhepa mice revealed the presence of necrotic foci in distinct hepatic lobes with 
yellowish color (Figure 6A). H&E staining of WT and Jnk1Δhepa livers showed severe 
cholestatic hepatitis with widespread bile infarcts - coincident with necrotic foci - 
along with bile ductular proliferation, portal edema and hepatocellular damage 
(Figure 6B+C). In contrast, Jnk1-/- mice exhibited signs of ductular proliferation but no 
necrotic foci (Figure 6B+C). Biliary infarcts in Jnk1-/- mice compared with WT and 
Jnk1Δhepa 4 weeks after BDL were dramatically reduced (Figure 6D). These data 
indicate that JNK1 expression in hepatocytes has no impact on hepatocellular injury 
in two different models of chronic experimental liver injury. 
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A                                                                           B 
 
      C                                                                     D 
Figure 6. Presence of necrotic foci and biliary infarcts in BDL-subjected liver specimens. (A) 
Macroscopic appearance of livers of WT, Jnk1-/- and Jnk1Δhepa mice 28 days after BDL with detail of 
the liver surface. Sham-operated mice were used as controls. (*) indicate yellow dots on liver surface. 
(B) Representative H&E staining of liver sections from livers of WT, Jnk1-/- and Jnk1Δhepa mice 28 days 
after BDL. Sham mice were used as controls. Arrows (↑) indicate necrotic foci. (C) Representative 
H&E staining of livers of WT, Jnk1-/- and Jnk1Δhepa mice showing areas of necrotic foci (*). (D) 
Quantification of bile infarcts of WT, Jnk1-/- and Jnk1Δhepa mice 28 days after BDL was performed by a 
pathologist (Prof. N. Gaßler, Institute of Pathology, UKA).  
 
As BDL triggers liver damage through biliary fibrosis, we analyzed biochemical 
markers 28 days after BDL. Plasma AST and ALT levels increased approximately 10-
fold in Jnk1Δhepa and WT but only 7-fold in Jnk1-/- mice compared with respective 
sham-operated animals (Figure 7A+B). Bile duct ligated Jnk1Δhepa and WT mice 
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exhibited significantly more cholestasis as characterized by hyperbilirubinemia with 
yellowish skin and alkaline phosphatase (AP) compared with Jnk1-/- mice (Figure 
7C+D).  
A                                                                       B 
 
C                                                                        D                                                                       
Figure 7. Biochemical markers of 28 days-BDL-subjected serum specimens. (A) Serum levels of 
AST were determined 28 days after BDL in SHAM, WT, Jnk1-/- Jnk1Δhepa mice.(B) ALT, (C) Bilirubin 
and (D) AP were determined 28 days after BDL in SHAM,WT, Jnk1-/- Jnk1Δhepa mice.  
 
Death of hepatic cells was examined by TUNEL staining. Jnk1-/- animals showed 
significantly less TUNEL-positive cells than WT and Jnk1Δhepa mice 28 days after 
CCl4 treatment (Figure 8A+B). Similarly, the percentage of TUNEL-positive cells in 
WT and Jnk1Δhepa livers was 1.8±0.3 and 1.6±0.4, 28 days after BDL, respectively. In 
contrast, significantly lower TUNEL-positive cells (1.0±0.1) were found in Jnk1-/- livers 
(Figure 8C+D).  
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A                                                              B 
         
C                                                                     D 
Figure 8. Analysis of apoptosis in livers from CCl4- and BDL-treated mice. (A) Representative 
TUNEL stainings were performed on frozen liver sections after 4 weeks of repeated CCl4 injections. (B) 
Quantification of TUNEL-positive cells in WT, Jnk1-/- and Jnk1Δhepa mice after 4 weeks of CCL4 
repeated injections. (C) Representative TUNEL stainings were performed on frozen liver sections after 
4 weeks of BDL surgery. Arrows (↑) indicate TUNEL-positive cells. Values are mean ± SEM from at 
least 8-10 mice per time point. (D) Quantification of TUNEL-positive cells in WT, Jnk1-/- and Jnk1Δhepa 
after 4 weeks of BDL surgery are shown. Arrows (↑) indicate TUNEL-positive cells. Values are mean ± 
SEM from at least 8-10 mice per group (*p<0.05; **p<0.01; ***p<0.001).  
 
3.2 JNK1 in NPCs determines hepatocyte proliferation after BDL and CCl4 
treatment.  
 
Acute and chronic liver injury is followed by a phase of hepatocyte proliferation 
in order to restore liver mass 79. Thus, we investigated changes in the expression of 
cell cycle markers. PCNA, Cyclin D and Cyclin A levels were strongly up-regulated in 
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Jnk1Δhepa and WT livers 4 weeks after BDL or after repetitive CCl4 treatment, 
respectively (Figure 9). In contrast, these changes were significantly less severe in 
Jnk1-/- mice suggesting reduced compensatory proliferation after injury in both 
experimental models (Figure 9). These results were further corroborated at the 
mRNA level.  
 
Figure 9. Expression of cell cycle markers of livers from CCl4- and BDL-treated liver specimens. 
Liver extracts from WT, Jnk1-/- and Jnk1Δhepa mice sacrificed 28 days after CCl4 treatment or BDL 
surgery. 
 
PCNA and Cyclin D were highly expressed in Jnk1Δhepa and WT livers after chronic 
liver injury and significantly lower in Jnk1-/- mice (Figure 10A-D).  
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Figure 10. mRNA expression analysis of liver samples after CCl4 and BDL treatment. The 
samples were subjected to RT-PCR to analyse the expression of PCNA in WT, Jnk1-/- and Jnk1Δhepa 
mice sacrificed 28 days after CCl4 treatment (A) or BDL surgery (B). The same samples were 
subjected to RT-PCR to analyse the expression of Cyclin D in WT, Jnk1-/- and Jnk1Δhepa mice 
sacrificed 28 days after CCl4 treatment (C) or BDL surgery (D). Values are mean ± SEM from at least 
8-10 mice per group (**p<0.01***; p<0.001).  
 
Moreover, quantification of cell proliferation with Ki-67 immunostaining demonstrated 
lower proliferation rates in Jnk1-/- compared with Jnk1Δhepa and WT livers treated with 
CCl4 or with BDL for 4 weeks (Figure 11A+B). 
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B 
Figure 11. Cell proliferation analysis in liver after CCl4 and BDL treatment. (A) 
Immunofluorescence staining for Ki-67 of liver cryosections after 4 weeks of repeated CCl4 injections 
(left panels). The results were quantified and represented as percentage of area fraction. (B) 
Immunofluorescence staining for Ki-67 of liver cryosections after 4 weeks of BDL (left panels). The 
results were quantified using Image J Software, represented as percentage of Area Fraction. Arrows 
(↑) indicate Ki-67-positive cells. Values are mean ± SEM from at least 8-10 mice per group (*p<0.05; 
***p< 0.001).  
 
3.3 JNK1 in NPCs promotes liver fibrogenesis. 
  
We next evaluated whether our findings were relevant for fibrosis progression 
and performed Sirius Red staining. Repeated CCl4 injections induced severe collagen 
deposition and septum formation in Jnk1Δhepa and WT livers, classified by two 
independent pathologists as bridging fibrosis (Figure 12A). In contrast, quantification 
of Sirius Red staining revealed significantly lower collagen fibre formation in Jnk1-/- 
mice (Figure 12A+B). The essential role of JNK1 in non-hepatocytes for fibrosis 
progression was also found in the BDL model. JNK1 knockout livers showed reduced 
signs of fibrosis compared with Jnk1Δhepa and WT mice 4 weeks after BDL (Figure 
12C+D). 
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A                                                               B 
 C                                                              D                                        
 
Figure 12. Sirius Red staining of liver samples after CCl4 and BDL treatment. (A,C) 
Representative Sirius red staining of liver paraffin sections from WT, Jnk1-/- and Jnk1Δhepa after 4 
weeks of CCl4 treatment (A) or BDL (C). (B, D) Sirius red staining were quantified using paraffin 
sections from WT, Jnk1-/- and Jnk1Δhepa livers after 4 weeks of CCl4 treatment (B) or BDL (D). 
 
 These findings were further validated by measuring α-SMA and Collagen IA1 
mRNA and protein expression (Fig 13A-G). Conclusively, these findings 
strengthened our previous results as detected by Sirius Red staining. Jnk1-/- livers 
show reduced α-SMA and Collagen IA1 expression compared with Jnk1Δhepa and WT 
animals, in both experimental models. 
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F 
 
G 
Figure 13. Liver fibrogenesis in liver after CCl4 and BDL treatment. (A, B) mRNA expression 
analysis of α-SMA was quantified by RT-PCR of liver samples taken from WT, Jnk1-/- and Jnk1Δhepa 
mice sacrificed after after 4 weeks of chronic CCl4 treatment (A) or BDL surgery (B). (C, D) mRNA 
expression analysis of Collagen IA1 was quantified by RT-PCR of liver samples taken from WT, Jnk1-/- 
and Jnk1Δhepa mice sacrificed 28 days after chronic CCl4 treatment (C) or BDL (D). Values are mean ± 
SEM from at least 8-10 mice per time point and condition. (E) Liver extracts from WT, Jnk1-/- and 
Jnk1Δhepa mice sacrificed 28 days after CCl4 treatment or BDL surgery were examined by immunoblot 
analysis by probing with antibodies to α-SMA, Collagen IA1 and GAPDH as indicated. (F, G) 
Quantification was performed on Collagen IA1 staining frozen sections from livers of WT, Jnk1-/- and 
Jnk1Δhepa after 4 weeks of CCl4 treatment (F) or BDL (G). Values are mean ± SEM from at least 8-10 
mice per group (*p<0.05; **p<0.01; ***p<0.001). 
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3.4 The WT recipient genotype after BMT determines the degree of liver injury. 
  
Our results demonstrate that JNK1 is crucial for liver fibrogenesis, but other 
cells rather than hepatocytes are relevant in mediating fibrosis. Hence we next 
investigated whether BMCs are essential in promoting liver fibrosis. We thus 
performed BMT experiments. WT and Jnk1-/- mice were lethally irradiated and 
reconstituted with either Jnk1-/- or WT bone marrow (BM). Five weeks after BMT, 
recipient mice were subjected to chronic CCl4 or BDL treatment for 28 days (Figure 
14A). 5 weeks after BMT, chimerism in the liver was confirmed by PCR which 
demonstrated successful BM reconstitution (Figure 14B). 
A 
B 
Figure 14. Schematic diagram of BMT and proof of BM reconstitution. (A) Scheme of the 
chimeras used for radiation and the experimental design of the study. (B) Liver DNA was prepared 
and PCR was performed from mice 9 weeks after BMT. The JNK1-specific bands for wt and JNK1-/- 
are indicated confirming successful chimerism in the liver after BMT. 
 
No apparent macroscopic differences were found between chimeric mice treated 
with repetitive doses of CCl4 for 4 weeks (Figure 15A). Histological analysis showed 
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no difference in hepatocellular damage but more infiltration of inflammatory cells in 
WT recipients transplanted with Jnk1-/- mice (Jnk1-/-ÆWT) (Figure 15B).  
A                                                                B 
Figure 15. Macroscopic appearance and H&E staining of livers from CCl4-treated mice after 
BMT. (A) Macroscopic appearance of livers of WT or Jnk1-/- mice transplanted with Jnk1-/- or WT bone 
marrow cells. 5 weeks later mice were treated with CCl4 for a period of 4 weeks. (B) Representative 
H&E staining of liver sections from these mice are shown.  
 
The BDL treated chimeric WT mice reconstituted with WT (WTÆWT) and Jnk1-/- 
BM (Jnk1-/-ÆWT) showed macroscopically yellowish dots on their surface (Figure 16 
A+B). In contrast, Jnk1-/- recipients transplanted with WT or Jnk1-/- BM (WT/Jnk1-/-
ÆJnk1-/-) showed no external signs of liver injury (Figure 16A+B). 
A                                                                 B 
Figure 16. Presence of necrotic foci and biliary infarcts of BDL-subjected liver specimens after 
BMT. (A) Macroscopic appearance of livers of WT or Jnk1-/- mice transplanted with Jnk1-/- or WT bone 
marrow cells are shown. 5 weeks after BMT mice were subjected to BDL and were sacrificed 28 days 
later. (*) indicates yellow dots on the liver surface. (B) Representative H&E staining of liver sections 
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from these mice. (↑) Bile infarcts corresponding to the yellow dots observed on the liver surface and 
histologically assigned as necrotic foci by an expert liver pathologist.  
 
Histological analysis of BDL-treated livers showed necrotic foci in WT recipient 
mice reconstituted with Jnk1-/- BM (Jnk1-/-ÆWT) or WT BM (WTÆWT) indicative of 
hepatocellular damage (Figure14 A,B). In contrast, Jnk1-/- mice reconstituted with 
either Jnk1-/- BM (Jnk1-/-ÆJnk1-/-) or WT BM (WTÆJnk1-/-) displayed presence of 
inflammatory cells and some ductular proliferation but significantly lower hepatic cell 
death compared with the WT recipient groups (Figure 17A,B). Along with these 
results, plasma AST (Figure 17C), ALT, Bilirubin and AP (Figure 17D-F) levels 
evidenced significantly higher liver damage after BDL in WT mice reconstituted with 
WT BM (WTÆWT) or Jnk1-/- BM (Jnk1-/-ÆWT). 
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E                                                              F 
 
 
Figure 17. Liver injury in BDL-subjected liver specimens after BMT. (A) Representative H/E 
staining of necrotic foci from WT and Jnk1-/- mice transplanted with Jnk1-/- or WT bone marrow cells 
and subjected to BDL for 4 weeks showing areas of necrotic foci (*). (B) Quantification of bile infarcts 
of WT and Jnk1-/- mice transplanted with Jnk1-/- or WT bone marrow cells treated with BDL for 28 days, 
was performed blinded by a pathologist. (C-F) Serum levels of AST (C), ALT (D), Bilirubin (E) and AP 
(F) were determined after BMT + BDL in Jnk1-/- or WT mice. Values are mean ± SEM from at least 6-8 
mice per group (**p<0.01; ***p<0.001). 
 
3.5 JNK1 in bone marrow derived cells has no relevance for liver fibrogenesis. 
  
Our first findings with BMT experiments revealed that BM-derived cells of WT 
or Jnk1-/- transplanted into WT or Jnk1-/- mice have no major impact on the injury 
phenotype of the livers of the respective recipients. Thus, we next studied how BMT 
affected liver fibrogenesis and analyzed matrix formation by Sirius red staining and 
quantified these results by ImageJ software (Figure 18A+B). Consistently, in both 
experimental models our observations showed that WT animals reconstituted with 
WT or Jnk1-/- BM showed more matrix deposition compared with Jnk1-/- mice 
reconstituted with Jnk1-/- or WT BM (Figure 18A+B). Accordingly, this analysis 
showed that the JNK1-dependent effect on liver fibrogenesis is primarily determined 
by non-BM derived cells. 
     In order to further support this observation, we performed Collagen IA1 protein 
immunostaining in the livers of the different groups after BMT followed by repetitive 
CCl4 treatment or BDL (Figure 18C+D). These results also demonstrated that the 
reconstituted WT recipient mice had significantly more Collagen IA1 deposition 
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compared with the chimeric Jnk1-/- animals. Therefore, the BMT experiments showed 
that the JNK1 status in BM-derived cells is of minor relevance for liver fibrogenesis in 
the BDL and the CCl4 model. 
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Figure 18. Liver fibrogenesis analysis in chimeric liver samples after CCl4 and BDL. (A, B) 
Representative Sirius red staining of liver paraffin sections from WT or Jnk1-/- mice transplanted with 
Jnk1-/- or WT bone marrow cells and subjected to CCl4 treatment (A) of BDL (B) for 4 weeks. (left 
panels). Quantification of the same samples is represented as positive area fraction of Sirius red 
staining(right panel). (C, D) Representative Collagen IA1 staining of liver frozen sections from WT or 
Jnk1-/- mice transplanted with Jnk1-/- or WT bone marrow cells and subjected to CCl4 treatment (C) or 
BDL (D) for 4 weeks. Values are mean ± SEM from at least 7 mice per group (*p<0.05; **p<0.01). 
 
3.6 Array analysis suggests that genes involved in matrix formation are 
decreased in Jnk1-/- mice. 
As our results suggested that other cells than BM-derived cells or hepatocytes 
are involved in mediating the pro-fibrogenic JNK1-dependent effect, we performed 
array analysis to potentially link the gene profile to a specific liver cell type. We 
applied microarray analysis to detect changes in mRNA expression between WT, 
Jnk1-/- and Jnk1Δhepa (Figure 19). We calculated the average expression of the sham-
operated mice and divided the log2 values of the individual mice by the mean of the 
sham. Log ratios were saved in a txt file and analyzed with the Multiple Experiment 
Viewer. First we selected the top 1000 variable genes in the dataset based on 
interquartile range and then selected genes associated with HSCs activation and 
hepatic fibrosis. A representative sample of these genes was then hierarchically 
clustered and statistically analyzed by Pearson correlation. The results as depicted in 
Figure 19 showed that genes involved HSCs activation, hepatic fibrosis and liver 
damage exhibit major changes between the knockout strains. HSCs-marker genes 
such as raet1d (retinoic acid early transcript-delta), or genes associated with hepatic 
fibrosis such as mmd2 (monocyte to macrophage differentiation-associated 2), gas1 
(growth arrest specific-1), and grem1 (gremlin), timp4 (tissue inhibitor 
metalloproteinase-4) or mmp7 (matrix metalloproteinase-7) were differentially 
clustered according to fold change. These genes were down-regulated in Jnk1-/- 
compared with WT and Jnk1Δhepa livers. Of notice, genes related to protection against 
fibrosis such as saa1 (serum amyloid-1) or saa2 (serum amyloid-1) were highly up-
regulated in Jnk1-/- and strongly down-regulated in Jnk1Δhepa mice (Figure 19). 
Therefore, our microarray data suggested that genes directly involved in matrix 
production showed specific differences in Jnk1-/- compared with Jnk1Δhepa and WT 
livers 28 days after BDL. 
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A 
Figure 19. Microarray showing genes involved in matrix formation and deposition are 
decreased in Jnk1-/- mice. Microarray was performed in WT, Jnk1-/- and Jnk1Δhepa; log2 expression 
values of the individual mice, were divided by the mean of the sham operated mice. Log ratios were 
saved in a txt file and analyzed with the Multiple Experiment Viewer. The selected up- and down-
regulated genes are shown (RED: Up-regulated; GREEN: Down-regulated, n=3, fold change -3.0-3.0).  
Microarray analysis suggested that cells directly involved in matrix production are 
associated with reduced fibrosis in Jnk1-/- livers. We thus analyzed α-SMA 
expression in liver paraffin sections to study HSCs activation during liver injury 
(Figure 20A+B). We found that lobular activated α-SMA HSCs in Jnk1-/- mice were 
less in number compared to WT and Jnk1Δhepa mice and that the septa are more 
slender, 28 days after CCl4 treatment (Figure 20A). Indeed, α-SMA positive activated 
HSCs were observed in a perisinusoidal pattern forming fine portal-central septa 
(Figure 20A). Moreover, 28 days after BDL, α-SMA positive cells were mainly portal 
myofibroblasts, surrounding ductular proliferation areas (Figure 20B). Periportal 
fibrosis and portal-portal septa were formed in WT and Jnk1Δhepa mice and 
significantly reduced in Jnk1-/- livers (Figure 20B), suggesting that HSCs are directly 
involved in mediating the JNK1-dependent pro-fibrogenic effect on liver fibrogenesis. 
Additionally, we performed CK19 staining in liver sections to investigate the 
pattern of ductular reaction during BDL-triggered liver injury (Figure 20C). WT and 
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Jnk1Δhepa mice exhited larger extension of the portal tract compared to the Jnk1-/- 
mice. Moreover, necrotic areas and periportal CK19 positive hepatocytes, a sign of 
periportal cholatestasis, were present in WT and Jnk1Δhepa mice but not in Jnk1-/- mice 
(Figure 20C).  
 
A 
 
 
 
 
 
 
 
 
 
B 
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C 
Figure 20. Activated HSCs analysis in vivo of liver samples after CCl4 and BDL. (A, B) 
Immunohistochemistry was performed on liver paraffin sections for α-SMA in livers of WT, Jnk1-/- and 
Jnk1Δhepa mice, 28 days after CCl4 (A) or BDL treatment (B). (C) Immunohistochemistry staining on 
liver paraffin sections for CK-19 in livers of WT, Jnk1-/- and Jnk1Δhepa mice, 28 days after BDL 
treatment. 
 
3.7 JNK1 is essential for HSCs transdifferentiation.  
 
The array analysis and immunohistochemistry strongly suggested that 
differences in HSCs activation are found during chronic liver injury. We thus tested 
the importance of Jnk1 for HSCs transdifferentiation into myofibroblasts. Primary 
HSCs from WT, Jnk1-/- and Jnk1Δhepa mice were isolated using a FACSAria based 
protocol (Figure 21A). In these cells proliferation, apoptosis and transdifferentiation 
was studied in vitro over a time period of 10 days. We first studied p-JNK and α-SMA 
expression in WT HSCs. Our results clearly showed that transdifferentiation and α-
SMA expression was associated with JNK activation (Figure 21B).  
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B 
 
 
 
Figure 21. JNK1 in HSCs is essential for the pathogenesis of liver fibrosis. Primary HSCs were 
isolated from WT, Jnk1-/- and Jnk1Δhepa mice. A total number of 150.000 cells were seeded in 6-well 
plates and cultivated for up to 10 days. (A) Gating strategy in the Cell Sorter FACSAria for the isolation 
of primary HSCs (B) Co-immunofluorescence staining for pJNK (red) and α-SMA (green) was 
performed in WT cells from day 4 to day 10 after isolation.  
 
Next, we quantified the total number of HSCs up to 10 days after isolation. The 
total number of living WT and Jnk1Δhepa HSCs increased continuously up to 10 days 
whereas proliferation in Jnk1-/- HSCs was significantly attenuated (Figure 22A). 
These differences of HSC proliferation were further strengthened using 
immunofluorescence stainings for Ki-67 and α-SMA. HSCs derived from Jnk1-/- mice 
showed significantly less Ki-67- and α-SMA-positivity compared with HSCs derived 
from WT or Jnk1Δhepa animals (Figure 22A+B).  
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Figure 22. JNK1 in HSCs is essential for their proliferation. (A) Morphology and cell density was 
confirmed by phase contrast microscopy at day 4 and day 7 after isolation. Jnk1-/- HSCs was 
significantly attenuated (upper middle panels).Primary HSCs from WT, Jnk1-/- and Jnk1Δhepa mice were 
co-stained for Ki-67 and α-SMA at day 4 and day 7 after isolation. (B) mRNA expression analysis of 
Collagen IA1 Primary HSCs from WT, Jnk1-/- and Jnk1Δhepa mice were quantified for Ki-67 positive 
cells after 7 days in culture.  
 
Additionally, we performed TUNEL analysis of seeded HSCs up to 10 days 
after isolation. In these experiments HSCs derived from Jnk1-/- livers showed more 
cell death compared with Jnk1Δhepa cells or WT cells (Figure 23A+B). 
Subsequently, we quantified mRNA expression of α-SMA, Collagen IA1 and 
PDGF-Rβ (Figure 23C-E), known to be activated during HSCs transdifferentiation. 
HSCs from Jnk1-/- mice showed down-regulation of α-SMA, Collagen IA1 and 
PDGFR-β compared with WT and Jnk1Δhepa -derived HSC (Figure 23C-E). Altogether, 
the in vitro experiments with primary HSCs confirmed the in vivo studies defining 
JNK1 as an essential factor involved in HSCs activation and transdifferentiation. 
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B                                                                   C 
 
 
D                                                                E 
 
Figure 23. Lack of JNK1 expression in HSCs triggers HSC apoptosis and reduces 
transdifferentiation. (A) Representative TUNEL staining of primary HSCs from WT, Jnk1-/- and 
Jnk1Δhepa mice at day 7 of culture, and quantification of positive cells (B). (C-E) mRNA expression 
analysis of Collagen IA1 (C), PDGFR-β (D) and α-SMA (E) was quantified by RT-PCR of samples 
taken from isolated primary HSCs after 7 days in culture. Values are mean ± SEM from at least 7 mice 
per group (*p<0.05, ***p<0.001). 
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4. Discussion 
 
JNK are members of the MAPK family involved in the regulation of cell death, 
proliferation, metabolism and inflammation80. JNK1 and JNK2 are both expressed in 
the liver. At present it is not well defined if these two genes have synergistic or 
antagonistic functions during the progression of acute and chronic liver diseases. 
One of the tasks to truly understand the role of JNK for liver physiology and 
pathophysiology is to characterize and identify their cell-type specific function under 
different conditions. Parenchymal and NPCs as well as immune infiltrating cells 
contribute to mechanisms of liver injury and repair. In this context, cell-type specific 
activation of JNK family members might be relevant to determine the outcome of liver 
disease.  
In the present study we were interested in defining the relevance of JNK1 
activation in different liver cell compartments during liver fibrosis. We used two widely 
accepted in vivo experimental models of liver fibrosis81-82; (i) the surgical BDL-model 
of biliary fibrosis and (ii) the pharmacological CCl4 model of globular fibrosis. For this 
approach we generated hepatocyte-specific JNK1 knockout mice. JNK1 complete 
knockout mice as well as the respective controls were included. Moreover, we 
performed BMT to investigate the relevance of JNK1 activation in bone marrow-
derived cells and investigated the contribution of JNK1 in vivo and in vitro in HSCs to 
define their function during liver fibrogenesis. Interestingly, our results demonstrated 
that JNK1 activation in HSCs plays an essential role during their transdifferentiation 
and thus we define JNK1 in HSCs as a profibrogenic mediator since deletion of JNK1 
reduces liver fibrogenesis. 
 
4.1 The contribution of JNK1 in hepatocytes and NPCs to chronic liver injury  
 
Earlier studies have examined the relevance of JNK activation not only in 
acute but also in chronic liver injury83. Especially JNK1 has been reported to play a 
crucial role in response to TNF84, Concanavalin A85, ischemia-reperfusion64, 80 
acetaminophen intoxication86, HFD87 and hepatic carcinogens88. Therefore, we first 
investigated the role of hepatocyte-specific JNK1 during chronic liver injury in the 
CCl4 and BDL model of liver fibrosis. The results show fellow as: Firstly, 
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macroscopical examination of 28 days-BDL-subjected liver specimens of WT and 
Jnk1Δhepa mice revealed no different of the presence of necrotic foci in distinct hepatic 
lobes. H&E staining of WT and Jnk1Δhepa livers also showed no differences 
concerning cholestatic hepatitis with widespread bile infarcts. In contrast, Jnk1-/- mice 
exhibited signs of ductular proliferation but no necrotic foci. Biliary infarcts in Jnk1-/- 
mice compared with WT and Jnk1Δhepa 4 weeks after BDL were dramatically reduced. 
For mice treated with CCl4, H&E staining of Jnk1Δhepa and WT livers revealed more 
cellular damage and centrilobular congestion of inflammatory cells compared to Jnk1-
/- mice, while WT and Jnk1Δhepa liver have the same phenotype. Plasma AST and ALT 
levels increased at same folds in Jnk1Δhepa and WT compared with respective sham-
operated animals. Moreover, Bile duct ligated Jnk1Δhepa and WT mice exhibited 
significantly more hyperbilirubinemia and AP compared with Jnk1-/- mice, but we did 
not find significant differences when WT and Jnk1Δhepa mice were compared. TUNEL 
staining shows Jnk1-/- animals showed significantly less TUNEL-positive cells than 
WT and Jnk1Δhepa mice 28 days after CCl4 and BDL treatment. However, WT and 
Jnk1Δhepa mice showed no difference.  In summary, these data indicate that JNK1 
expression in hepatocytes has no impact on hepatocellular injury in two different 
models of chronic experimental liver injury, which means that JNK1 in hepatocytes 
had no major impact on the progression of liver disease. 
However, the role of JNK in apoptosis remains highly controversial89-91. Some 
authors suggested a pro-apoptotic role of JNK1 during TNF-induced apoptosis in 
vitro63 and in vivo64. Under normal circumstances, transient JNK activation confers 
cytoprotection92-93. However, our preliminary results (Cubero et al, unpublished) 
suggest that NF-κB has a major impact on the role of JNK1 during chronic liver injury. 
Deletion of the IKK regulatory subunit IKKγ/NEMO blocks NF-κB activation. As a 
consequence, the NF-kB-dependent anti-oxidative response is severely impaired, 
triggering prolonged JNK1 activation and resulting in increased apoptosis (Cubero et 
al, unpublished results).  
 
4.2 The role of JNK1 in hepatocytes and NPCs to liver fibrosis 
 
In our experiments we found that repeated CCl4 injections and BDL induced 
severe collagen deposition and septum formation in Jnk1Δhepa and WT livers, 
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classified by Sirius Red staining. In contrast, quantification of Sirius Red staining 
revealed significantly lower collagen fibre formation in Jnk1-/- livers. These findings 
were further validated by measuring α-SMA and Collagen IA1 mRNA and protein 
expression. Jnk1-/- livers show reduced α-SMA and Collagen IA1 expression 
compared with Jnk1Δhepa and WT animals, in both experimental models. 
Several reports have supported the hypothesis that JNK1 is necessary for the 
development of fibrosis in organs such as lung and kidney94-95. Indeed, Kluwe and 
collaborators59 had previously reported that genetic deletion of JNK1 or its 
pharmacological inhibition by SP600125 did not improve hepatocellular injury as 
measured by transaminase levels or changes in bile infarcts in the CCl4 and BDL- 
model up to three weeks. In line with these results, we observed no difference during 
the early phase of liver injury in both experimental models using Jnk1-/-, Jnk1Δhepa or 
WT animals (data not shown). However, liver injury was significantly reduced in Jnk1-
/- animals after 4 weeks of CCl4 or BDL treatment. A possible explanation for these 
differences is the duration of chronic injury since prolonged liver damage results in 
stronger fibrosis and consequently in liver cirrhosis96 which might be also secondary 
to the observed effect of impaired HSCs transdifferentiation in Jnk1-/- animals.  
In Jnk1-/- livers reduced hepatocyte proliferation was observed in both 
experimental models of liver injury compared with Jnk1Δhepa or WT animals. Since 
Jnk1-/- animals also showed reduced liver injury, it is likely that this observation is 
rather a consequence than a primary JNK1-dependent effect. The role of JNK1 
during liver regeneration has been investigated. Recent studies88, 97 suggest a cell-
specific and crucial role of JNK in liver regeneration. In accordance with the study by 
Das97, our data would strengthen the finding that JNK1 activation during the 
regenerative response is not important in liver parenchymal cells but in other cells 
which contribute to the proliferative response of hepatocytes. PCNA, Cyclin D and 
Cyclin A levels on the mRNA and protein lever were strongly up-regulated in 
Jnk1Δhepa and WT livers 4 weeks after BDL or after repetitive CCl4 treatment, 
respectively. In contrast, these changes were significantly less severe in Jnk1-/- mice 
suggesting reduced compensatory proliferation after injury in both experimental 
models. Moreover, quantification of cell proliferation with Ki-67 immunostaining 
demonstrated lower proliferation rates in Jnk1-/- compared with Jnk1Δhepa and WT 
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livers treated with CCl4 or with BDL for 4 weeks. Interestingly, WT and Jnk1Δhepa mice 
showed the same rate of hepatocyte proliferation. 
 
 
4.3 The analysis of the function of JNK1 in BM-derived cells during liver injury 
 
As the experiments using Jnk1Δhepa mice clearly demonstrated that JNK1 in 
hepatocytes has no impact on the progression of liver fibrosis in both models of injury, 
we next investigated the contribution of BM-derived cells. Previous studies revealed 
that JNK1 activation in e.g. KCs is relevant during hepatic inflammation and thus in 
the end might contribute to liver fibrosis98-99. Additionally, KCs can interact with HSCs, 
accelerate their activation, and promote their fibrogenic responses in vitro99. To this 
end, lethally irradiated WT or Jnk1-/- mice were reconstituted with bone marrow from 
WT or Jnk1-/- donors and treated with antibiotics to reduce postoperative infection 
and inflammation.  
In our experiments, KCs recovery was ensured since we performed CCl4 or BDL 
5 weeks after the injection of BM-derived cells. Unexpectedly, our results showed 
that JNK1 in BM-derived cells does not significantly contribute to liver fibrosis. These 
results were further confirmed by transplanting WT or Jnk1-/- BM into Jnk1Δhepa 
animals. Evidence is as follows: Firstly, the BDL treated chimeric WT mice 
reconstituted with WT (WTÆWT) and Jnk1-/- BM (Jnk1-/-ÆWT) showed 
macroscopically yellowish dots and necrotic foci in HE staining while Jnk1-/- recipients 
transplanted with either WT or Jnk1-/- BM (WT/Jnk1-/-ÆJnk1-/-) showed no external 
signs of liver injury. Secondly , Along with the first results, plasma AST, ALT, Bilirubin 
and AP levels evidenced significantly higher liver damage after BDL in WT mice 
reconstituted with WT BM (WTÆWT) or Jnk1-/- BM (Jnk1-/-ÆWT). Thirdly, in both 
fibrosis model, WT animals reconstituted with WT or Jnk1-/- BM showed more matrix 
deposition compared with Jnk1-/- mice reconstituted with Jnk1-/- or WT BM by Sirius 
red staining and Collagen IA1 immunostaining in the livers.  
These experiments showed no significant differences in liver fibrogenesis in 
hepatocyte-specific JNK1 knockout animals reconstituted with WT or Jnk1-/- BM-
derived cells (data not shown). 
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4.4 Assess the role of JNK1 in HSCs in vivo and in vitro 
 
The knockout and BM experiments strongly suggested that NPCs are essential in 
mediating the JNK1-dependent pro-fibrogenic effect during chronic liver injury. 
Among NPCs, cholangiocytes, non-bone marrow-derived KC, endothelial cells or 
HSCs could be responsible for mediating the JNK1-dependent effect on liver fibrosis. 
Therefore, at this point, we followed two different strategies to identify precisely the 
NPCs important in mediating this effect. We included array analysis and 
immunohistochemistry studies, performed by an experienced pathologist, 4 weeks 
after chronic liver injury. Microarray analysis suggested HSCs-marker genes raet1d, 
or genes associated with hepatic fibrosis such as mmd2, gas1, and grem1, timp4 (or 
mmp7 were differentially clustered according to fold change. These genes were 
down-regulated in Jnk1-/- compared with WT and Jnk1Δhepa livers. Moreover, genes 
related to protection against fibrosis such as saa1 or saa2 were highly up-regulated 
in Jnk1-/- and strongly down-regulated in Jnk1Δhepa mice. Immunohistochemistry 
staining showed that α-SMA positive activated HSCs in Jnk1-/- mice were less in 
number compared to WT and Jnk1Δhepa mice and that the septa are more slender. 
Both independent analyses pointed at the HSC compartment as the cell population 
involved in mediating the JNK1-dependent pro-fibrogenic effect on liver fibrogenesis.  
To test the relevance of our in vivo observation we isolated primary HSCs from 
WT, Jnk1Δhepa and Jnk1-/- mice. Here, we used a recently established novel cell 
sorting technique developed in our Department which provides high HSC purity5. The 
‘conventional’ HSCs isolation using the diverse density gradient methods has for a 
long time remained the ‘gold standard’ method, mainly due to the fact that it allows 
for isolating fairly large numbers of HSCs with acceptable purity100. However, 
conventional HSC purification protocols result in a purity of only approximately 75% 
HSCs100. Due to these challenges, our team has established protocols to isolate 
HSCs by FACS. HSCs from mice were purified by cell sorting using simply their high 
side scatter of incident light101. Starting from crude cell fractions that were 50–70% 
enriched by conventional density centrifugation, the obtained cell purity after sorting 
(in which 1.4 ± 0.4 million cells were sorted per hour) was found to be over 96% and 
the viability of resulting cells was approximately 90%, as measured by Trypan blue 
exclusion testing . 
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HSCs from WT, Jnk1Δhepa and Jnk1-/- were cultured for up to 10 days. These 
results visibly strengthened the in vivo findings and demonstrated that JNK1 is crucial 
in the early stages of normal HSCs activation as well as in later phases when these 
cells express α-SMA. Our data show that the lower profibrogenic response of Jnk1−/− 
mice is due to the poor rate of proliferation and survival of Jnk1-/- HSCs associated 
with decreased expression of α-SMA, Collagen IA1 and PDGFR-β. Moreover, 
apoptosis of Jnk1-/- HSCs helps to prevent the fibrogenic cascade, a phenomenon 
also observed in C/EBP-β deleted mice102. 
We used a knockout for JNK1 in hepatocytes to specifically define the role of cell-
type JNK1 in liver fibrogenesis. Here, we report for the first time that JNK1 in 
hepatocytes is not important for the development of liver fibrosis. Additionally, the 
BMT experiments strongly argue against the hypothesis that JNK1 knockout in bone 
marrow-derived cells have an effect on hepatic fibrosis. Finally, our data point at 
JNK1 as an essential pro-fibrogenic kinase in HSCs and portal myfibroblasts for the 
pathogenesis of different types of liver fibrosis (biliary and hepatocytic). Altogether, 
our results shed new light and contribute to previous findings59 in the yet undefined 
field of liver fibrosis and activation of the MAPK signalling pathway. In summary, our 
results suggest that cell-type specific inhibition of JNK1 in HSCs might be an 
attractive therapeutic approach for treating liver fibrosis, thus opening a new door for 
the treatment of patients. 
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5. Summary 
 
Liver fibrosis is the body’s response to persistant hepatic injury, which fre-
quently triggers liver cirrhosis and HCC. JNKs are activated in response to stimuli 
such as inflammatory cytokines, bacterial products, oxidative stress, toxins, drugs, 
and metabolic changes. Indeed, JNK contribute to ECM deposition during 
myofibroblast differentiation suggesting a potential role for the JNK genes in liver 
fibrogenesis. However, the specific role of the JNK genes, and specifically of JNK1, 
during liver fibrosis remains elusive. 
The present study aimed to investigate target cell types and molecular 
mechanisms involved in mediating JNK1-dependent effects. WT, Jnk1−/− and 
Jnk1Δhepa mice were subjected to BDL or chronic CCl4 treatment. Additionally, the 
contribution of bone-marrow derived cells and HSC was investigated. Serum markers 
of liver damage (liver transaminases, AP and bilirubin) and liver histology revealed 
reduced injury in Jnk1−/− compared to WT and Jnk1Δhepa mice. Hepatocyte cell death 
and proliferation was reduced in Jnk1−/− compared to WT and Jnk1Δhepa livers. 
Parameters of liver fibrosis such as Sirius Red staining as well as Collagen IA1 and 
α-SMA expression were down-regulated in Jnk1−/− compared to WT and Jnk1Δhepa 
livers, 4 weeks after CCl4 or BDL. BMT experiments excluded bone marrow derived 
cells from having a major impact on the JNK1-dependent effect on fibrogenesis. 
Primary HSCs from Jnk1−/− livers showed reduced transdifferentiation compared with 
WT and Jnk1Δhepa-derived HSCs.  
We report for the first time that JNK1 in hepatocytes is not important for the 
development of liver fibrosis. Additionally, the BMT experiments strongly argue 
against the hypothesis that JNK1 knockout in bone marrow-derived cells have an 
effect on hepatic fibrosis. Finally, our data point at JNK1 as an essential pro-fibro-
genic kinase in HSCs and portal myfibroblasts for the pathogenesis of different types 
of liver fibrosis (biliary and hepatocytic). In the future cell-type specific inhibition of 
JNK1 in HSCs might be an attractive therapeutic approach for treating liver fibrosis, 
thus opening a new door for the treatment of patients. 
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6. Zusammenfassung 
 
Leberfibrose resultiert aus einer chronischen Leberschädigung, die sich im 
Verlauf zur Leberzirrhose bis hin zum hepatozellulären Karzinom (HCC) entwickeln 
kann. Die Jun-Kinasen (JNK) werden durch unterschiedliche Stimuli, wie Zytokine, 
bakterielle Mediatoren, oxidativen Stress, Toxine oder bestimmte 
Stoffwechselprodukte aktiviert. Sie sind wichtig für den Aufbau der extrazellulären 
Matrix im Rahmen der Reifung von Myofibroblasten, weshalb den JNK eine 
entscheidende Bedeutung bei der Entstehung der Leberfibrose zukommen kann. Die 
zugrundeliegenden Mechanismen und insbesondere die Funktionen der JNK- 
Isoformen für die Fibroseentstehung, insbesondere von JNK1, sind bisher unklar.  
Ziel dieser Arbeit war es, die molekularen Mechanismen und die zelltyp- 
spezifische Bedeutung von JNK1 für die Leberfibroseentstehung zu charakterisieren. 
An Wildtypmäusen (WT), konstitutiven JNK1 Knockoutmäusen (Jnk1−/−) und 
hepatozytenspezifischen Knockoutmäusen (Jnk1Δhepa) wurden zwei etablierte 
Modelle der Fibroseentstehung in der Leber untersucht. Dies sind die 
Gallengangsligatur (BDL) und die chronische Leberschädigung durch CCl4, weiterhin 
erfolgten Knochenmarkstransplantationen und in vitro Experimente mit HSCs. 
Serummarker für Leberschädigung wie Transaminasen, alkalische Phosphatase und 
Biliurubin sowie die histologische Aufarbeitung zeigten eine verminderte 
Leberschädigung in Jnk1−/− im Vergleich zu WT and Jnk1Δhepa Mäusen. Sowohl die 
Apoptose- als auch die Zellproliferation von Hepatozyten waren vermindert in Jnk1−/− 
im Vergleich zu WT and Jnk1Δhepa Lebern. Die Leberfibrose, quantifiziert anhand von 
Sirius Red Färbungen, Messungen der Collagen IA1 und α-SMA Expression war 
weniger ausgeprägt in Jnk1−/− im Vergleich zu WT und Jnk1Δhepa Lebern 4 Wochen 
nach CCl4 oder BDL. Durch die Ergebnisse der BMT Experimente konnte ein 
wesentlicher Effekt von Zellen der myeloischen Reihe bei der JNK1-abhängigen 
Leberfibrose ausgeschlossen werden. Weiterführende Experimente ergaben, dass 
insbesondere die JNK1-Expression in HSCs eine wesentliche Rolle für die 
Fibroseentstehung spielt. 
Durch diese Arbeit wurde erstmalig gezeigt, dass JNK1 in Hepatozyten keine 
entscheidende Rolle bei der Fibroseentstehung spielt. Zusätzlich sprechen die 
Ergebnisse der BMT Experimente gegen einen relevanten Effekt von JNK1 in Zellen 
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der myeloischen Reihe. Die Daten deuten auf eine substantielle Rolle von JNK1 als 
profibrotische Proteinkinase in HSCs und portalen Myofibroblasten hin. In Zukunft 
könnte eine HSCs-spezifische Modulation der JNK1 Aktivität als therapeutischer 
Ansatz bei Patienten mit Leberfibrose und Zirrhose in Frage kommen.  
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8. Appendix 
 
Abbreviations 
 
Abbreviations  Full Name 
α-SMA α-smooth muscle actin 
AF2 Activation function 2 
ALT  Alanine-aminotransferase  
AP  Apurinic/apirimidinic  
APS  Ammoniumperoxodisulfat  
AST  Aspartate-aminotransferase  
BCL-2 B-cell lymphoma 2 
BDL  Bile duct ligation 
BM Bone marrow 
BMC Bone marrow cells 
BMT Bone marrow transplant 
BSA  Bovine Serum Albumin  
Cat  Catalase  
Ccn A  Cyclin A  
Ccn D  Cyclin D  
Ccn E  Cyclin E  
cDNA  Complementary DNA  
c-Myc v-myc avian myelocytomatosis viral 
oncogene homolog 
COL1A1 Collagen type I α1 
DAB  3,3´-diamino benzidine  
DAPI  4,6-diamino-2-phenylindole  
DMEM  Dulbecco´s modified Eagle´s medium  
DNA  Desoxyribonucleic acid  
dNTP  Desoxyribonukleotidtrisphospate  
DR Death Domain 
DTT  Dithiothreitol  
Δhepa  Hepatocyte-specific knockout 
EDTA  Ethylendiamintetraacetic acid  
ECL  Enhanced chemiluminescence  
ECM Extracellular matrix 
EGF  Epidermal growth factor  
ER Endoplasmic reticulum 
ERK Extracellular signal-regulated kinase 
FACS  Fluorescence activated cell sorting  
FAS TNF receptor superfamily 
Fb  Fibronectin  
FCS  Fetal calf serum  
FFA Free fatty acids 
FITC  Fluoresceinisothocyanat  
GAPDH  Glyceraldehyde 3-phosphate 
dehydrogenase  
 
 
 
  Appendix 
 73 
 
GFAP Glial Fibrillary Acidic Protein 
H&E  Hematoxylin and eosin  
HCC  Hepatocellular carcinoma  
HCV Hepatitis C Virus 
HRP  Horseradish peroxydase  
HSC Hepatic Stellate Cells 
IF  Immunofluorescence  
IHC  Immunohistochemistry  
ISR Insuling receptor 
JIP JNK-interacting protein 
JNK  c-Jun N-terminal kinase  
KC Kupffer cell 
Ki-67 cell cycle specific protein encoded by the 
MKI67 gene 
LMW  Low molecular weight  
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinase 
Mcl-1 Myeloid cell leukemia 1 
MCP1 Monocyte chemotactic protein-1 
MMP2  Matrix Metalloprotease also known as 
collagenase 2 
Mn-SOD  Manganese superoxide dismutase  
MOPS  Morpholinopropansulfon  
mRNA  Messenger RNA  
NAFLD  Nonalcoholic fatty liver disease  
NASH  Nonalcoholic steatohepatitis  
NF-kB nuclear factor kappa-light-chain-
enhancer of activated B cells 
NPC non-parenchymal cells 
OD  Optical density  
OPN Osteopontin 
PBS  Phosphate buffered saline  
PBS-T  PBS-Tween  
PCNA  Proliferating cell nuclear antigen  
PCR  Polymerase chain reaction  
PDGF Platelet derived growth factor 
PEST  prolin (P), Glutamic acid (E), Serine (S), 
Threonine (T)  
PFA  Paraformaldehyde  
PH  Partial hepatectomy  
RANTES regulated upon activation, normal T cell 
expressed and secreted 
RNA  Ribonucleic acid  
RPMI  Roswell Park Memorial Institute  
ROS reactive oxygen species 
RT  Room temperature  
SDS  Sodium dodecyl sulphate  
SEC Sinusoidal endothelial cells 
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Ser  Serine  
SOCS Suppressor Of Cytokine Signaling 
TAE  Tris Acetate EDTA Buffer  
TBS  Tris buffered saline  
TBS-T Tris buffered saline supplemented with 
Tween 20 
TE  Tris-EDTA-Buffer  
TEMED  N´,N,N´,N´-Tetramethyldiamine  
TGF-beta  Transforming growth factor beta  
Thr  Threonine  
TIMP-1 Tissue inhibitor of metalloproteinase-1 
TNF-α tumor necrosis factor-α 
Tris  2-Amino-2(hydroxymethyl)-1,3-propandiol  
TUNEL  Terminal deoxynucleotidyl transferase 
dUTP nick end labeling  
Tween 20  Polyoxyethylensorbitanmonolaureat  
v/v  Volume per Volume  
WT  Wild type  
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der Promotionsordnung 
 
 
Hiermit erkläre ich, Herr Gang Zhao an Eides statt, dass ich folgende in der von mir 
selbständig erstellten Dissertation “JNK1 in Hepatic Stellate Cells is a crucial 
mediator of liver fibrogenesis in mice ” dargestellten Ergebnisse erhoben habe: 
 
Durchführung sämtlicher dargestellter Experimente, sowie deren statistische 
Auswertung (ggf. unter Hilfestellung der  unten aufgelisteten Personen). 
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